



<b>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</b>	<i>Application Number</i>	09/914,046
	<i>Filing Date</i>	
	<i>First Named Inventor</i>	
	<i>Group Art Unit</i>	
	<i>Examiner Name</i>	
	<i>Attorney Docket Number</i>	2444-105
<i>Title of the Invention:</i> TARGETED LIPOSOME GENE DELIVERY		

**DECLARATION**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

I, Esther Chang, declare that:

1. I am the same Esther Chang named as an inventor on the above-referenced patent application.

2. I received a B.A. degree in biology from Fu Jen University in Taiwan in 1968 and a Ph.D. in microbiology from Southern Illinois University in 1974. From 1982-1994 I held the positions of Assistant Professor, Associate Professor, and then Professor in the Department of Pathology, Uniformed Services University of the Health Sciences in Bethesda, MD. I also was a Research Professor in their Department of Surgery and the Director of their Tumor Biology Program. From 1994-1996 I held the position of Professor of Surgery (Research), Division of Otolaryngology/Head and Neck Surgery in the Department of Surgery

**BEST AVAILABLE COPY**

U.S. Application No. 09/914,046  
Inventor: Esther H. CHANG

at Stanford University Medical Center. Since 1996, I have held the position of Professor of Surgery (Consultant) there. I currently also hold the positions of Professor of Otolaryngology, Department of Otolaryngology/Head & Neck Surgery and Professor of Oncology, Department of Oncology, at the Georgetown University Medical Center, Lombardi Cancer Center, and have held those positions since 1996 and 1999, respectively. A copy of my curriculum vitae is attached hereto.

3. I have read the Office Action issued by the U.S. Patent and Trademark Office on November 28, 2004, and understand the grounds of rejection set forth therein.

4. In several rejections the examiner cited a paper by MacLean et al., and asserted that it discussed a method for coupling antibodies to liposomes in which an antibody or fragment thereof can be bound to the liposome via a sulfur atom that was part of a sulfhydryl group on the antibody or antibody fragment, thus indicating that she believed that the immunoliposome complexes claimed in the present application were taught in the prior art.

The discussion to which the examiner referred was part of a discussion of methods known in the art for coupling antibodies to liposomes, provided on page 329 of the MacLean et al. paper. Specifically, the method to which the examiner referred is method

U.S. Application No. 09/914,046  
Inventor: Esther H. CHANG

iii). MacLean et al. provided that succinimidyl-maleimide crosslinker could be used to attach antibodies containing sulfhydryl groups to liposomes, and that "Fab' antibody fragments already contain sulfhydryl groups but other antibodies may be modified using sulfhydryl generators," citing a 1983 paper by Duncan et al., a copy of which is attached hereto as Attachment 1.

5. The method taught by Duncan et al. would not be effective for binding an scFv fragment to a liposome. Duncan et al. teach introducing a sulfhydryl group onto an antibody by treatment with N-succinimidyl S-acetylthioacetate (SATA). SATA can alkylate any exposed amino group in the protein and does so randomly. This results in a so-called "Poisson distribution" of alkylated molecules. This means that only about 36% of the molecules are monosubstituted, about 33% have multiple substitutions and about 31% are unsubstituted. "Hence, single substitutions can be obtained with only a small fraction of IgG molecules and this is probably true for most proteins" (page 72, column 1). "Multiple substitutions would be expected in a significant proportion of the molecules" (page 72, sentence bridging columns 1 and 2). Moreover, there is no way of directing the substitution to a specific amino acid. This has two distinct negative implications for scFv fragments.

First, these multiple substitutions form polymers which will

U.S. Application No. 09/914,046  
Inventor: Esther H. CHANG

block the epitope on the scFv that binds to the receptor such that the desired immunoliposome complex cannot be formed. Second, even if such polymers don't form, there is no way to direct the binding of the antibody fragment to the maleimide-DOPE in the liposome. Thus, even if the scFv is only monosubstituted, it would only be by chance that the right amino acid would carry the substitution, such that the epitope that binds to the receptor would be exposed and available for binding to the liposome.

6. The authors of the Duncan et al. paper realize this drawback. They noted that "it is apparent that fewer potential polymerization sites will result if the single active group mentioned above is inserted into the peroxidase rather than the IgG" (page 72, column 3). Thus, they realize that this method does not work well for antibodies.

7. Both of these problems result in loss of biological activity. This does not happen in the method used in our application to produce scFv-liposome complexes. The DNA encoding the scFv is molecularly engineered such that a single -SH is introduced, the protein refolds properly to its natural state, and introduced -SH will not interfere with the binding of the antibody fragment to its receptor.

8. A further drawback to the approach taught by Duncan et al. is that before the antibody can be conjugated to The

U.S. Application No. 09/914,046  
Inventor: Esther H. CHANG


maleimide, The substituted protein has to be deprotected using either hydroxyl amine or an excess of another thiol which has to be "scrupulously removed before proceeding with the conjugation" (page 68, columns 1-2). These increased manipulations also will result in decreased biological activity.

9. Thus, this method is not useful for the conjugation of scFv to cationic liposomes. This is evidenced by the fact that although Duncan et al. published their paper in 1983, no scFv directly conjugated to cationic liposomes had been reported in the art as of the date we filed our patent application over 15 years later. The prevailing wisdom at the time of our invention was that scFv simply could not be used for immunoliposomes because they were simply too small and too fragile and efforts to modify them to provide a group which could react with a reactive group of the liposome would result in the loss of biological activity.


10. I further declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Codes, and that such willful false statements may jeopardize the validity of the application and any patent issuing

U.S. Application No. 09/914,046  
Inventor: Esther H. CHANG

thereon.

  
\_\_\_\_\_  
Esther Chang, Ph.D.

5/31/05  
Date



## CURRICULUM VITAE

10/7/2002

### PERSONAL

Name: Esther H. Chang  
Place of Birth: Chungking, China  
Citizenship: U.S. Citizen  
Marital Status: Married with 1 daughter (Harford)  
Work Address: Departments of Oncology & Otolaryngology  
Georgetown University Medical Center  
Lombardi Cancer Center/TRB E420  
3970 Reservoir Road NW  
Washington, DC 20057-1469  
Phone: (202) 687-8418  
FAX: (202) 687-8434

Home Address: 7508 Vale Street  
Chevy Chase, MD 20815  
Phone: (301) 913-5964  
FAX: (301) 913-5284

Email Address: change@georgetown.edu

### EDUCATION

Fu Jen University, Taiwan	B.A.	1968	Biology
Southern Illinois University	Ph.D.	1974	Microbiology

### PROFESSIONAL APPOINTMENTS

Trainee	1967 - 1968
U.S. Naval Medical Research Unit No. 2 Taiwan	
Research Assistant Southern Illinois University	1968 - 1971
Teaching Assistant in Immunology and Virology Southern Illinois University	1971 - 1972
Research Associate Southern Illinois University	1972 - 1973
Special Dissertation Fellow Southern Illinois University	1973 - 1974
Visiting Fellow National Institutes of Health	1974 - 1977
Visiting Associate National Institutes of Health	1977 - 1978
Cancer Expert National Cancer Institute	1978 - 1982
Assistant Professor Department of Pathology Uniformed Services University of the Health Sciences	1982 - 1983
Associate Professor and Coordinator for Medical Genetics Curriculum	1983 - 1988

Department of Pathology Uniformed Services University of the Health Sciences Professor, Department of Pathology Research Professor, Department of Surgery Coordinator for Medical Genetics Curriculum Director, Tumor Biology Program Uniformed Services University of the Health Sciences	1988 - 1994
Professor of Surgery (Research) Division of Otolaryngology/Head & Neck Surgery Department of Surgery Stanford University Medical Center	1994 - 1996
Professor of Surgery (Consultant) Division of Otolaryngology/Head & Neck Surgery Department of Surgery Stanford University Medical Center	1996-Present
Professor of Otolaryngology Department of Otolaryngology/Head & Neck Surgery Georgetown University Medical Center Lombardi Cancer Center	1996-Present
Professor of Oncology and Otolaryngology Departments of Oncology and Otolaryngology Georgetown University Medical Center Lombardi Cancer Center	1999-Present
<b>HONORS AND OTHER SPECIAL RECOGNITION</b>	
Honor Society of Phi Kappa Phi	1972
Special Dissertation Fellow Southern Illinois University	1973 - 1974
Author, two papers in 100 most-cited papers in Life Sciences, Current Contents, November 5, 1984	1982 - 1983
Conference Organizer-International Conference on Molecular Biology of Neoplasia Taipai, Taiwan	1984
<i>Ad Hoc</i> Reviewer for NIH Study Section	1985
One of six awardees, Visiting Scholar Exchange Program, National Academy of Sciences, American Council of Learned Societies and Social Science Research Council	1986 - 1987
Member, Merit Review Committee, USUHS	1987 - 1989
<i>Ad hoc</i> Member, Review Panel for Assessment of Department of Energy research projects on chemical toxicology	1989
Member, Faculty Senate Education Committee, USUHS	1990 - 1991
Member, Editorial Board of Antisense Research and Development	1990 - Present



Member, Steering Committee on Prescribing of Drugs by Military Psychologists	1991
Chairman, Subcommittee for Faculty Resources for the Educational Program, Institutional Self-Study at USUHS	1991 - 1993
Member, Scientific Advisory Committee on Design Study for Life Span Experiments in Mice on Carcinogenesis and Biological Effects of Heavy Charged Particles, NASA	1992 - 1994
Chairman, Subcommittee to Examine Faculty, Middle States Association Reaccreditation Self-Study, USUHS	1992 - 1993
<i>Ad hoc</i> Member, Special Review Committee, Epidemiology, NCI	1992
Author, one Nature paper in top ten most cited papers in medicine Science Watch, September, 1992	1992
Member, Board of Scientific Counselors, Division of Cancer Biology, Diagnosis and Centers, National Cancer Institute	1993 - 1995
Member, NASA Life and Microgravity Sciences and Applications Advisory Committee	1994 - Present
Member, Interim <i>ad hoc</i> Board of Scientific Counselors, National Cancer Institute, NIH	1995 - 1996
Chair, Molecular Genetics Study Section, U.S. Army Breast Cancer Research Program	1997
Chair, Experimental Gene Therapy, Program Committee AACR Annual Meeting	1999
Member, Board of Scientific Advisors, National Cancer Institute	1999 - 2004
Member, Editorial Board of Cancer Gene Therapy	1999 - Present
Member, Scientific Program Committee. Chair, Gene Therapy Program NCI-EORTC-AACR Symposium	1999
Distinguished Alumni, Fu Jen University	1999
10 <sup>th</sup> Lecturer, Stewart Lectureship	2000
Member, NASA Focus Group - National Academy of Sciences, Committee on Science, Engineering, and Public Policy	2000
Member, Committee of Scientific Advisors, United States Military Cancer Institute	2001 - Present
<i>Ad hoc</i> member, Experimental Therapeutics I + II, Study Section, NIH	2002
Organizer, Conference on "Tumor Specific Delivery by Non-Viral Systems" Maui, Feb. 2003 Sponsored by NCI	2002-2003
Approximately 10 annual invited lectures at national and international conferences and academic and research institutes	1982 - Present

#### DISSERTATION TITLE

Comparative Studies of Growth Patterns of Ganjam Virus in CE, BHK and VERO and *Aedes albopictus* Cells

#### RESEARCH ACTIVITIES

#### Undergraduate

Insect tissue culture. Studied growth pattern of insect line cells (*Bombyx*, *Aedes* and *Antheraea*) and adapted two lines into hemolymph-free media. Gained some experience in the growth of Japanese Encephalitis Virus in insect cells and newborn mice.

#### Graduate School

Arboviruses (Togaviruses). Electron microscopy. Compared the growth of VSV in insect cells and chicken embryo fibroblasts. Determined the viral RNA profiles in each cell line.

Characterized Ganjam Virus, an ungrouped arbovirus.

#### Postgraduate

RNA tumor viruses - interferon effect. Studied interferon's inhibitory effect on the replication of murine leukemia virus. (In Robert M. Friedman's laboratory, National Institute of Arthritis, Metabolic and Digestive Diseases, NIH).

Molecular genetics. Cloned and characterized murine leukemia and sarcoma viruses. Investigated the origin and the functional organization of Harvey murine sarcoma virus. Molecularly cloned four DNA fragments containing human homologous sequences of *v-ras* (2 Harvey and 2 Kirsten) and demonstrated their oncogenic potentials. Studied potential human oncogenes. (In Douglas R. Lowy's Laboratory, Dermatology Branch, National Cancer Institute, NIH).

#### Current

- 1) Molecular genetic basis of familial cancer syndrome and the involvement of human oncogenes and tumor suppressor genes in carcinogenesis.
- 2) Modulation of oncogene expression by sequence-specific antisense oligonucleotides.
- 3) Molecular basis of cellular radioresistance and radioprotection.
- 4) Tumor Suppressor Gene Therapy for Cancer (Head and Neck, Breast and Prostate)
- 5) Ligand directed, tumor-targeted liposome-based systemic gene delivery

#### **MEMBERSHIP IN ORGANIZATIONS AND PROFESSIONAL AFFILIATIONS**

Honor Society of Phi Kappa Phi	1973-
American Association for the Advancement of Science	1983-
Society of Chinese Bioscientists in America	1988-
The Wound Healing Society	1991-
American Association for Cancer Research	1993-
American Society of Gene Therapy	1997-

#### **PUBLICATIONS - ESTHER H. CHANG**

1. R. M. Friedman, E. H. CHANG, J.M. Ramseur and M.W. Myers. Interferon-directed inhibition of chronic murine leukemia virus production in cell cultures: Lack of effect of intracellular viral markers. *J. Virol.* 16: 569-574 (1975).
2. R. M. Friedman, J.C. Costa, J.M. Ramseur, M.W. Myers, F.T. Jay and E. H. CHANG. Persistence of the viral genome in interferon-treated cells infected with oncogenic or nononcogenic viruses. *The J. Infectious Diseases* 133: A43-A50 (1976).
3. R. M. Friedman, F. T. Jay, E. H. CHANG, M. W. Myers, J. M. Ramseur, S. J. Mims, T. J. Triche, and P.K.Y. Wong. Interferon-directed inhibition of chronic murine leukemia virus production in cell cultures. *In: Control of Neoplasia by Modulation of the Immune System.* (M.A. Chirigos, ed.), Raven Press, New York (1977), pp. 347-359.
4. R. M. Friedman, E. F. Grollman, E. H. CHANG, L. D. Kohn, G. Lee and F. T. Jay. Interferon and glycoprotein hormones. *In: Texas Reports on Biology and Medicine* (1977), pp. 326-329.
5. R. M. Friedman and E. H. CHANG. Interferon action. Possible mechanisms of antiviral activity. *In: Interferons and Their Actions* (M. Stewart, ed.) CRC Handbook Series (1977), pp. 145-152.
6. E. H. CHANG, S. J. Mims, T. J. Triche, and R. M. Friedman. Interferon inhibits mouse leukemia virus release: An electron microscope study. *J. Gen. Viron.* 34: 363-367 (1977).
7. P. K. Y. Wong, P. H. Yuen, R. Macleod, E. H. CHANG, M. W. Myers, and R. M. Friedman. The effect of interferon on *de novo* infection of Moloney murine leukemia virus. *Cell* 10: 245-252 (1977).
8. E. H. CHANG, M. W. Myers, P. K. Y. Wong, and R. M. Friedman. The inhibitory effect of interferon on a temperature-sensitive mutant of Moloney murine leukemia virus. *Virology* 77: 625-636 (1977).
9. E. H. CHANG, and R. M. Friedman. A large glycoprotein of Moloney leukemia virus derived from interferon-treated cells. *Biochem. Biophys. Res. Commun.* 77: 392-398 (1977).

10. E. H. CHANG, F. T. Jay and R. M. Friedman. Physical and morphological alteration in the membrane of AKR cells following interferon treatment and their correlation with the establishment of the antiviral state. *Proc. Natl. Acad. Sci.* 75: 1859-1863 (1978).
11. E. H. CHANG, E. F. Grollman, F.T. Jay, G. Lee, L. D. Kohn and R.M. Friedman. Membrane alterations following interferon treatment. *In: Human interferon*. W. Alton Jones Cell Science Center, Lake Placid, New York (1978), pp. 85-99.
12. A. K. Bandyopadhyay, E. H. CHANG, C. C. Levy and R. M. Friedman. Structural abnormalities in murine leukemia viruses produced by interferon-treated cells. *Biochem. Biophys. Res. Commun.* 87: 983-988 (1979).
13. G. L. Hager, E. H. CHANG, H. W. Chan, C. F. Garon, M. A. Israel, M. A. Martin, E. M. Scolnick and D. R. Lowy. Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: Initial structural and biological characterization. *J. Virol.* 31: 795-809 (1979).
14. H. W. Chan, C. F. Garon, E. H. CHANG, D. R. Lowy, G. L. Hager, E. M. Scolnick, R. Repaske and M. A. Martin. Molecular cloning of the Harvey sarcoma virus circular DNA intermediates: II. Further structural analyses. *J. Virol.* 33: 845-855. (1980).
15. A. I. Oliff, G. L. Hager, E. H. CHANG, E. M. Scolnick, H. W. Chan and D. R. Lowy. Transfection of molecularly cloned Friend murine leukemia virus DNA yields a highly leukemogenic helper independent type C virus. *J. Virol.* 33: 475-486 (1980).
16. S. L. Berger, M. J. Hitchcock, K. C. Zoon, C. S. Birkenmeier, R. M. Friedman and E. H. CHANG. Characterization of interferon messenger RNA synthesis in namalva cells. *J. Biol. Chem.* 255: 2955-2961 (1980).
17. E. H. CHANG, J. Maryak, D. M. Wei, T. Y. Shih, R. Shober, H. L. Cheung, R. W. Ellis, G. L. Hager, E. M. Scolnick and D. R. Lowy. Functional organization of the Harvey murine sarcoma virus genome. *J. Virol.* 35: 76-92 (1980).
18. R. W. Ellis, D. DeFeo, J. M. Maryak, H. A. Young, T. Y. Shih, E. H. CHANG, D. R. Lowy and E. M. Scolnick. A dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. *J. Virol.* 36: 408-420 (1980).
19. E. H. CHANG and D. R. Lowy. Transformation by molecularly cloned Harvey murine sarcoma virus DNA. *J. Supramol. Struct.* 9 (Supp. 4): 237 (1980).
20. E. M. Scolnick, T. Y. Shih, J. Maryak, R. Ellis, E. H. CHANG and D. Lowy. Guanine nucleotide binding activity of *src* gene product of rat-derived murine sarcoma viruses. *Ann. N.Y. Acad. Sci.* 354: 398-409 (1980).
21. E. H. CHANG, R. W. Ellis, E. M. Scolnick and D. R. Lowy. Transformation by cloned Harvey murine sarcoma virus DNA: Efficiency increased by long terminal repeat DNA. *Science* 210: 1249-1251 (1980).
22. D. DeFeo, M. A. Gonda, H. A. Young, E. H. CHANG, D. R. Lowy, E. M. Scolnick and R. W. Ellis. Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. *Proc. Natl. Acad. Sci.* 78: 3328-3332 (1981).
23. D.R. Lowy, R.W. Ellis, D. DeFeo, E. H. CHANG, M.A. Gonda, H.A. Young, N. Tsuchida, T.Y. Shih and E.M. Scolnick. The cellular p21 sarc genes represent a family of divergent normal genes which have the capacity to transform mouse cells. *In: RNA Tumor Viruses*, New York, Cold Spring Harbor (1981), p. 294.
24. D.R. Lowy, R.W. Ellis, D. DeFeo, E. H. CHANG, M.A. Gonda, A. Young, T.Y. Shih and E.M. Scolnick. The family of cellular P21 sarc genes. *In: Intl. Union of Microbiol. Soc., Virology Division* (1981), p. 462.
25. E. H. CHANG, D.R. Lowy, M. Gonda, D. DeFeo, E.M. Scolnick and R.W. Ellis. The p21 gene family: Human and rodent DNA sequences homologous to the transforming genes of Harvey and Kirsten murine sarcoma viruses. *In: Advances in Comparative Leukemia Research* (1981), pp. 379-380.
26. D. R. Lowy, E. H. CHANG, R. W. Ellis, D. DeFeo and E. M. Scolnick. Elevated levels of an evolutionarily conserved normal rat protein can induce cellular transformation. *Clin. Res.* 29(2): 428 (1981).
27. S. K. Chattopadhyay, E. H. CHANG, M. R. Lander, R. W. Ellis, E. M. Scolnick and D. R. Lowy. Selective amplification of *onc* genes in mammalian species. *Nature* 296: 361-363 (1982).
28. D. R. Lowy, E. H. CHANG, R. M. Ellis, M. A. Gonda, T. Shih, D. DeFeo and E. M. Scolnick. Harvey and Kirsten sarcoma viruses and the P-21 gene family. *J. Cell Biochem. Suppl.* 6: 194 (1982).

29. E. H. CHANG, M. A. Gonda, R. W. Ellis, E. M. Scolnick and D. R. Lowy. The human genome contains four genes homologous to the transforming genes of Harvey and Kirsten murine sarcoma viruses. *Proc. Natl. Acad. Sci.* 79: 4848-4852 (1982).
30. E. H. CHANG, M. A. Furth, E. M. Scolnick and D. R. Lowy. Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. *Nature* 297: 497-483 (1982).
31. D. R. Lowy, M. A. Gonda, M. E. Furth, R. W. Ellis, E. M. Scolnick, and E. H. CHANG. Tumorigenic transformation of mammalian cells induced by elevated levels of a normal human *onc* protein. *Clin. Res.* 30(2): 421 (1982).
32. C. J. Tabin, S. M. Bradley, C. L. Borgmann, R. A. Weinberg, A. G. Papageorge, E. M. Scolnick, R. Dhar, R. Lowy and E. H. CHANG. Mechanism of activation of a human oncogene. *Nature* 300: 143-149 (1982).
33. B. D. Crawford, E. H. CHANG, J. L. Goodwin, C. E. Hildebrand, P. M. Kraemer, J. L. Longmire and R. D. Palmiter. *J. Cell Biochem. Suppl.* 7: 135 (1983).
34. E. H. CHANG, M.A. Gonda, M.E. Furth, J.L. Goodwin, S.E. Yu, R.W. Ellis, E.M. Scolnick and D.R. Lowy. Characterization of four members of the p21 gene family isolated from normal human genomic DNA and demonstration of their oncogenic potential. *In: Gene Transfer and Cancer*, Raven Press, New York (1983), pp. 189-197.
35. E. H. CHANG, M.A. Gonda, E.M. Scolnick and D.R. Lowy. Characterization of 4 divergent human genomic clones homologous to the transforming p21 genes of Harvey and KiMuSV. *In: Gene to Protein—Translation into Biotechnology*, American Press (1983), p. 512.
36. D.R. Lowy, M.A. Gonda, M.A. Furth, R.W. Ellis, E.M. Scolnick and E. H. CHANG. The human genes homologous to p21 *ras* viral oncogenes. *In: Tumor Viruses and Differentiation*, Alan R. Liss, Inc., (1983), pp. 435-444.
37. D. Samid, E. H. CHANG and R.M. Friedman. Revertants from interferon-treated mouse cells transformed by a human oncogene. *In: The Biology of the Interferon System*, Elsevier Science Publishers, (1983), pp. 359-360.
38. M. S. McCoy, J. J. Toole, J. M. Cunningham, E. H. CHANG, D. R. Lowy and R. A. Weinberg. Characterization of a human colon/lung carcinoma oncogene. *Nature* 302: 79-81 (1983).
39. S. J. O'Brien, W. G. Nash, J. L. Goodwin, D. R. Lowy and E. H. CHANG. Dispersion of the *ras* family of transforming genes to four different chromosomes in man. *Nature* 302: 839-842 (1983).
40. M. R. Pincus, J. van Reswoude, J. B. Harford, E. H. CHANG and R. D. Klausner. Prediction of the three-dimensional structure of the transforming region of the EJ/T24 human bladder oncogene product and its normal cellular homologue. *Proc. Natl. Acad. Sci.* 80: 5253-5257 (1983).
41. S. J. O'Brien, W. G. Nash, R. Bauer, E. H. CHANG and L. J. Seigel. Trends in chromosomal and oncogene evolution in vertebrates. "Uses and Standardization in Vertebrate Culture Cells" (M. K. Paterson, ed.), *IN VITRO Monograph No. 5*: Gaithersburg Tissue Culture Association (1984), pp. 204-214.
42. D. Samid, E. H. CHANG and R. M. Friedman. Biochemical correlates of reversion in interferon-treated mouse cells transformed by a human oncogene. *Biochem. Biophys. Res. Commun.* 119: 21-28 (1984).
43. D. Samid, E. H. CHANG and R. M. Friedman. Inhibition by interferon of transformation induced by a human *ras* oncogene. *Biochem. Biophys. Res. Commun.* 126(1): 509-516 (1985).
44. D. Samid, Z. Schaff, E. H. CHANG and R.M. Friedman. Reduction in *ras* expression accompanies phenotypic reversion of interferon-treated, c-Ha-*ras* oncogene transformed mouse cells. *In: The Biology of the Interferon System* (H. Kirchner and H. Shellekens, eds.), Elsevier, Amsterdam (1985), pp. 189-198.
45. D. Samid, Z. Schaff, E. H. CHANG and R. M. Friedman. Interferon-induced modulation of human *ras* oncogene expression. *Endocoids. In: Progress in Clinical and Biological Research*, Vol. 192 (H. Lal, F. La Bella and J. Lane, eds.), Alan R. Liss, New York (1985), pp. 265-268.
46. D. Samid, E. H. CHANG and R.M. Friedman. Specific inhibition by interferon of oncogene-induced transformation. *In: Sero Symposium Publications*, Vol. 24 (F. Dianzani and G.B. Rossi, eds.), Raven Press, New York, (1985), pp. 425-422.

47. D. Samid, D.M. Flessate, J.J. Greene, E. H. CHANG and R.M. Friedman. Mechanisms of Antioncogenic activity of interferon in the 2-5A System: Molecular and clinical aspects of the interferon-regulated pathway. In: Prigin. Clinical and Biological Research, Vol. 202, (B.R.G. Williams and R.H. Silverman, eds.), Alan R. Liss, New York (1985), pp. 203-210.
48. D. Samid, E. H. CHANG and R.M. Friedman. Regulation of *ras*-expression by interferon. In: Proc. Asian Congress Pharmacol., (1985), pp. 343-364.
49. E. H. CHANG, J.K. Lin, and P. C. Huang, eds. Molecular Biology of Neoplasia. Academia Sinica, 1985
50. E. H. CHANG. Viral and cellular oncogenes. In: Molecular Biology of Neoplasia. (E.H. Chang, J.K. Lin and P.C. Huang, eds.) Academia Sinica - Taipei, Taiwan (1985), pp. 191-203.
51. D. Samid, E. H. CHANG, and R. M. Friedman. Biological and morphological characteristics of phenotypic revertants appearing in interferon-treated mouse cells transformed by a human oncogene. *J. Exp. Path.* 2(3): 211-222 (1985).
52. E. H. CHANG, P. L. Morgan, E. Lee-Lawlor, K. Pirollo, E. A. White, P. N. Tschlis and D. H. Patrick. Pathogenicity of retroviruses containing either normal human c-Ha-*ras* 1 or bladder carcinoma EJ/T24 *ras* gene. *J. Exp. Path.* 2: 177-190 (1985).
53. R. L. Stallings, R. Black, B. D. Crawford and E. H. CHANG. Assignment of *ras* protooncogenes in Chinese hamster: Implications for linkage conservation. *Cytogenet. Cell Genet.* 43: 2-5 (1986).
54. E. H. CHANG, R. Black, T. Masnyk and J.B. Harford. Effect of interferon on growth of A431 cells and expression of EGF receptors. In: Advances in Gene Technology: Molecular Biology of the Endocrine System. (D. Puett, *et al*, eds.), Proc. 18th Annual Miami Winter Symposium, 1986, pp. 370-371.
55. E. H. CHANG, R. Black, Z.Q. Zou, T. Masnyk, J. Ridge, P. Noguchi and J.B. Harford. Interferon modulates growth of A431 cells and expression of EGF receptors. In: Interferons as Cell Growth Inhibition and Antitumor Factors. (R.M. Friedman, T. Merigan and T. Sreevalsan, eds.), Alan R. Liss, New York (1986), pp. 335-350.
56. E. H. CHANG. Oncogenes and familial cancer syndrome. CAPA 86 Conference Proceedings, College Park, MD, 1986, pp. 21-29.
57. E. H. CHANG, K. F. Pirollo, Z. Q. Zou, H. Y. Cheung, E. L. Lawlor, R. Garner, E. White, W. B. Bernstein, J. F. Fraumeni, Jr. and W. A. Blattner. Oncogenes in radioresistant, non-cancerous fibroblasts from a cancer-prone family. *Science* 237: 1036-1039 (1987).
58. E. H. CHANG, J. Ridge, R. Black Z. Q. Zou, T. Masnyk, P. Noguchi and J. B. Harford. Interferon-induces altered oncogene expression and terminal differentiation in A431 cells. *Proc. Soc. Exp. Biol. Med.* 186: 319-326 (1987).
59. R. L. Black, Z. P. Yu, D. Brown and E. H. CHANG. Modulation of oncogene expression by epidermal growth factor and -interferon in A431 squamous cells. *J. Biol. Regulators Hemeo. Agents* 2: 35-44 (1988).
60. H. Blanche, E. H. CHANG, J. Dausset and H. M. Cann. A fragment of the human c-Ki-*ras* 1 pseudogene (HGM9 gene symbol KRASIP), localized to 6p12-p11, detects 3 allele, moderately polymorphic RFLP. *Nucl. Acid. Res.* 16: 1652 (1988).
61. W. Bernstein, Z. Q. Zou, R. J. Black, K. F. Pirollo and E. H. CHANG. Association of interferon induced growth inhibition and modulation of expidermal growth factor receptor gene expression in squamous cell carcinoma cell lines *J. Biol. Regulators Hemeo. Agents* 2: 186-192 (1988).
62. E. H. CHANG, R. Black, J. Ridge, W. Richtsmeier and J.B. Harford. Induction of altered oncogene expression and differentiation in squamous cell carcinoma cells in monolayers and three-dimensional cultures. In: The Status of Differentiation Therapy of Cancer (S. Waxman, G.B. Rossi and F. Takaku, eds.), Raven Press (1988), pp. 63-77.
63. P. S. Miller, L. Aurelian, K.R. Blake, E. CHANG, J.M. Kean, B.L. Lee, S.B. Lin, A. Murakami and P.O.P. Ts'o. Antisense oligonucleoside methyl-phosphonates. In: Current Communications in Molecular Biology. Antisense RNA and DNA (D. Melton, ed.), Cold Spring Harbor Lab., Cold Spring Harbor, New York, 1988, pp. 41-45.
64. E. H. CHANG. Specificity of methylphosphonate oligomers as down-modulators for *ras* expression. In: NCI/NIAID Workshop on Anti-Sense Oligonucleotides as Therapeutic Agents, Annapolis, MD, 1987 (1988), pp. 91-96.

65. K. F. Pirollo, R. Garner, S. Yuan, L. Li, W. A. Blattner and **E. H. CHANG**. *Raf* involvement in the simultaneous genetic transfer of the radioresistant and transforming phenotypes. *Int. J. Radiat. Biol.* **55**: 783-796 (1989).
66. D. Brown, Z. P. Yu, P. Miller, K. Blake, C. Wei, H. F. Kang, R. J. Black, P. O. P. Ts'o and **E. H. CHANG**. Modulation of *ras* expression by anti-sense nonionic deoxyoligonucleotide analogs. *Oncogene Res.* **4**: 243-252 (1989).
67. Z. P. Yu, D. F. Chen, R. J. Black, K. Blake, P. O. P. Ts'o, P. Miller and **E. H. CHANG**. Sequence specific inhibition of *in vitro* translation of mutated or normal *ras* p21. *J. Exp. Path.* **4**: 97-108 (1989).
68. **E. H. CHANG**, Z. P. Yu, K. Shimizuka, W. D. Wilson, A. Strekowska and G. Zon. Comparison of efficacy of modified anti-*ras* oligodeoxynucleotides. *Anti-Cancer Drug Design* **4**: 221-232 (1989).
69. W. J. Richtsmeier, W. M. Koch, W. P. McGuire, M. E. Poole and **E. H. CHANG**. A phase I-II study of advanced head and neck squamous carcinoma in patients treated with rHUIFN- $\gamma$ : Immunologic and histopathologic monitoring of patients. *Arch. Otolaryngol.* **116**: 1271-1277 (1990).
70. S. Srivastava, Z. Q. Zou, K. Pirollo, W. Blattner and **E. H. CHANG**. Germline transmission of a mutated p53 in a cancer-prone family with Li-Fraumini Syndrome. *Nature* **348**: 747-749 (1990).
71. J. M. Cunningham, G. E. Francis, K. F. Pirollo and **E. H. CHANG**. Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer. *Brit J. Cancer* **63**: 29-36 (1991).
72. **E. H. CHANG** and P. Miller. *Ras*, an inner membrane transducer of stimuli. In: *Prospects for Antisense Nucleic Acid Therapy of Cancer and Viral Infection*. (E. Wickstrom, ed.), Alan Liss, Inc., New York, pp. 115-124 (1991).
73. S. Srivastava, Z.Q. Zou, K. Pirollo, D. Tong, V. Sykes, K. Devadas, J. Miao, Y. Chen, W. Blattner and **E. H. CHANG**. An inherited p53 point mutation in a cancer-prone family with Li-Fraumeni Syndrome. In: *Neoplastic Transformation in Human Cell Culture*. (J.S. Rhim and A. Dritschilo, eds.), The Humana Press Inc., Totowa, NJ, pp. 124-134 (1991).
74. J. Ridge, J. Muller, P. Noguchi and **E. H. CHANG**. Interferon induces terminal differentiation in squamous carcinoma cells (A431). *In Vitro* **27A**: 417-424 (1991).
75. **E. H. CHANG**, P. Miller, C. Cushman, K. Devadas, K. F. Pirollo, P. O. P. Ts'o and Z. P. Yu. Antisense inhibition of *ras* p21 expression that is sensitive to a point mutation. *Biochemistry* **30**: 8283-8286 (1991).
76. T. McDaniel, D. Carbone, T. Takahashi, P. Chumakov, **E. H. CHANG**, K. F. Pirollo, J. Yin, Y. Huang, S. J. Meltzer. The *MspI* polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. *Nucleic Acids Research* **19**(17): 4796 (1991).
77. **E. H. CHANG**. The Application of Antisense in Altered Gene Expression: Antisense Inhibition of *ras* p21 Expression that contains a point mutation. *Clin. Chem.* **38**: 454-455 (1992).
78. S. Srivastava, Y. A. Tong, K. Davadas, Z. Q. Zou, V. W. Sykes, Y. Chen, W. A. Blattner, K. F. Pirollo and **E. H. CHANG**. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared "second hit" on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni Syndrome. *Oncogene* **7**: 987-991 (1992).
79. S. Srivastava, Y. A. Tong, K. Davadas, Z. Q. Zou, Y. Chen, K. F. Pirollo and **E. H. CHANG**. The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines. *Carcinogenesis* **13**: 1273-1275 (1992).
80. J. W. Moul, S. M. Theune, **E. H. CHANG**. Detection of *ras* mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization. *Genes, Chromosomes and Cancer* **5**: 109-118 (1992).
81. J. W. Moul, P. A. Friedrichs, R. S. Lance, S. M. Theune, **E. H. CHANG**. Infrequent *ras* oncogene mutations in human prostate cancer. *The Prostate* **20**: 327-338 (1992).
82. P. O. P. Ts'o, L. Aurelian, **E. H. CHANG**, and P. S. Miller. Non-ionic oligonucleotide analogues (Matagen IV) as anticodic agents in duplex and triplex formation. *Annals of the New York Academy of Sciences* **660**: 159-175 (1992).
83. Y. Huang, S. J. Meltzer, J. Yin, Y. Tong, **E. H. CHANG**, S. Srivastava, T. McDaniel, R. F. Boynton, and Z. Q. Zou. Altered mRNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. *Cancer Research* **53**: 1889-1894 (1993).

84. K. F. Pirollo, Y. A. Tong, Z. Villegas, Y. Chen and E. H. CHANG. Oncogene Transformed NIH/3T3 Cells Display Radiation Resistance Levels Indicative of a Signal Transduction Pathway Leading to the Radiation Resistant Phenotype. **Radiation Research** 135: 234-243 (1993).
85. S. Srivastava, S. Wang, Y. A. Tong, K. F. Pirollo and E. H. CHANG. Several Mutant p53 Proteins Detected in Cancer-Prone Families with Li-Fraumeni Syndrome Exhibit Transdominant Effects on the Biochemical Properties of the Wild-Type p53. **Oncogene** 8: 2449-2456 (1993).
86. J. W. Moul, J. T. Bishoff, S. M. Theune and E. H. CHANG. Absent ras Gene Mutations In Human Adrenal Cortical Neoplasms and Pheochromocytomas. **The Journal of Urology** 149: 1389-1394 (1993).
87. S. Srivastava, S. Wang, Y. A. Tong, Z. M. Hao and E. H. CHANG. Dominant Negative Effect of a Germ-line Mutant p53: A Step Fostering Tumorigenesis. **Cancer Research** 53: 4452-4455 (1993).
88. E. J. Kuhn, R. A. Kurnot, I. A. Sesterhenn, E. H. CHANG, and J. W. Moul. Expression of the c-erbB-2 (HER-2/neu) Oncoprotein in Human Prostatic Carcinoma. **The Journal of Urology** 150: 1427-1433 (1993).
89. R. Prashad, F. M. Price, K. F. Pirollo, E. H. CHANG, and K. K. Sanford. Cytogenic Response to G<sub>2</sub> Phase x-irradiation in Relation to DNA Repair and Radiosensitivity in a Cancer-Prone Family with Li-Fraumeni Syndrome. **Radiation Research** 136: 236-240 (1993).
90. U. Kasid, K. Pirollo, A. Dritschido, and E. H. CHANG. Oncogenic basis of radiation resistance. **Advances in Cancer Research** 61: 195-233 (1993).
91. M. F. Janat, S. Srivastava, K. Devadas, G. A. Chin, K. F. Pirollo and E. H. CHANG. Inhibition of the Retinoblastoma (RB) Protein Phosphorylation by the Synergistic Effect of Interferon- $\gamma$  and Tumor Necrosis Factor- $\alpha$ . **Molecular and Cellular Differentiation** 2(3): 241-253 (1994).
92. K.F. Pirollo, X.Y. Lin, Z.M. Hao, Z. Villegas and E. H. CHANG. Molecular Mechanisms of Cellular Radioresistance and Radiosensitivity. In: *Radiation and the Gastrointestinal Tract*. (A. Dubois, G.L. King, and D.R. Livengood, eds.) CRC Press, pp. 129-147 (1995).
93. K.F. Pirollo, Z. Hao, A. Rait, C.W. Ho, and E. H. CHANG. Evidence Supporting A Signal Transduction Pathway Leading to the Radiation Resistant Phenotype in Human Tumor Cells. **Biochemical Biophysical Research Communications** 230: 196-201 (1997).
94. L. Xu, K.F. Pirollo, and E. H. CHANG. Transferrin-Liposome Mediated Sensitization of Squamous Cell Carcinoma of the Head and Neck to Radiation Therapy. **Human Gene Therapy** 8: 467-475 (1997).
95. E. H. CHANG, Z. Hao, A. Rait, Y.J. Jang, W.E. Fee, H.H. Sussman, G. Murphy, P. Ryan, Y. Chiang, K.F. Pirollo. Restoration of the G1 Checkpoint and the Apoptotic Pathway Mediated by Wild-type P53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy. **Archives of Otolaryngology-Head & Neck Surgery** 123: 507-512 (1997).
96. K. F. Pirollo, Z. Hao, A. Rait, Y.J. Jang, W.E. Fee Jr., P. Ryan, Y. Chiang, E.H. CHANG, P53 Mediated Sensitization of Squamous Cell Carcinoma of the Head and Neck to Radiotherapy. **Oncogene** 14: 1735-1746 (1997).
97. S. Suy, W.B. Anderson, P. Dent, E.H. CHANG, U. Kasid. Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells. **Oncogene** 15: 53-61 (1997).
98. S. J. O'Brien, S. Cevario, J.S. Martenson, M.E. Thompson, W. Nash, E.H. CHANG, J. M. Graves, J.A. Spencer, K.-W. Cho, H. Tsujimoto, L.A. Lyons. Comparative Gene Mapping in the Domestic Cat (*Felis catus*). **J Hered.** 88: 408-414, (1997).
99. L. Xu, K.F. Pirollo, A. Rait, A. Murray, E.H. CHANG. Systemic p53 Gene Therapy in Combination Radiation Results in Human Tumor Regression. **Tumor-Targeting** 4: 92-114 (1999).
100. A. Rait, J.E. Krygier, K.F. Pirollo, and E.H. CHANG. Sensitization of Breast Cancer to Taxol by Antisense HER-2 Oligonucleotides. **Antisense and Nucleic Acid Drug Development**. 9 403-408 (1999).
101. L. Xu, K.F. Pirollo, W. Tang, A. Rait, and E.H. CHANG. Transferrin-Liposome-Mediated Systemic p53 Gene Therapy in Combination with Radiation Results in Regression of Human Head and Neck Cancer Xenografts. **Human Gene Therapy** 10: 2941-2952 (1999).

102. E. H. CHANG, K.F. Pirollo, L.Xu. Targeted p53 Gene Therapy Mediated Radiosensitization and Chemosensitization. in: *Cancer Drug Discovery and Development*. (J.S. Gutkind, ed). **The Humane Press Inc., Totowa, NJ.** pp. 521-538 (1999).
103. A. Rait, K.F. Pirollo, D. Will, A. Peyman, V. Rait, E. Uhlmann, and E. H. CHANG. 3' End-Conjugates of Minimally Phosphorothioate-Protected Oligonucleotides with 1-0-Hexadecylglycerol: Synthesis and Anti-*ras* Activity in Radiation-Resistant Cells. **Bioconjugate Chemistry** 11: 153-160 (2000).
104. A. Rait, E. Uhlmann, A. Peyman, D.W. Will, and E.H. CHANG. Inhibition of p21 Synthesis Using Partially Phosphorothioate Modified Antisense Oligonucleotides Directed against Ha-*ras*. **Anti-Cancer Drugs** 11: 181-191 (2000).
105. K. F. Pirollo, L. Xu and E.H. CHANG. p53 Non-viral Gene Delivery, **Current Opinion in Molecular Therapeutics** 2: 168-175 (2000)
106. E. H. CHANG, K.F. Pirollo and K.B. Bouker. Tp53 Gene Therapy: A Key to Modulating Resistance to AntiCancer Therapies? **Molecular Medicine Today** 6: 358-364 (2000)
107. K. F. Pirollo, K. B Bouker and E.H. CHANG. Does p53 status influence tumor response to anticancer therapies? **Anti-Cancer Drugs** 11: 419-432 (2000).
108. L. Xu, K.F. Pirollo, and E.H. CHANG. Tumor -Targeted p53-Genes Enhance the Efficacy of Conventional Chemo/Radiotherapy. **Journal of Controlled Release** 74(1-3):115-128 (2001).
109. A. Rait, V. Rait, K. F. Pirollo, J.E. Krieger,, and E.H. CHANG, Inhibitory Effects of the Combination of HER-2/erbB-2 Antisense Oligonucleotide and Chemotherapeutic Agents Used for Treatment of Human Breast Cancer Cells. **Cancer Gene Therapy** 8:728-739 (2001).
110. Z. A. Sherif, S. Nakai, K.F. Pirollo, A. Rait, and E.H. CHANG. Down-modulation of bFGF-Binding Protein Expression Following Restoration of p53 Function-A Possible Mechanism for the Bystander Effect. **Cancer Gene Therapy** 8:771-781 (2001).
111. L. Xu, W.H. Tang, C.C. Huang, W. Alexander, L.M. Xiang, K.F. Pirollo, A. Rait, and E.H. Chang. Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv. **Molecular Medicine** 7: 723-734 (2001)
112. L. Xu, et al., E.H. Chang. Self-assembled Virus-mimicking Nanostructure for High Efficiency Tumor-targeted Gene Delivery. **Human Gene Therapy** 13: 469-481 (2002)
113. L. Xu, C-C, Huang, W-Q, Huang, W-H, Tang, A. Rait, Y-Z, Yin, M. Cruz, L. Xiang, K.F. Pirollo, and E.H. CHANG. Systemic Tumor-Targeted Gene Delivery by Anti-Transferrin Receptor scFv-Immunoliposomes. **Molecular Cancer Therapeutics** 1: 337-346 (2002)
114. A. Rait, K.F. Pirollo, L.M. Xiang, D. Ulick, and E.H. Chang. Tumor-Targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels. **Molecular Medicine** 8(8); 476-487 (2002)
115. K.F. Pirollo, L. Xu and E.H. Chang. Immunoliposomes: A Targeted Delivery Tool for Cancer Treatment in Vector Targeting for Therapeutic Gene Delivery. (D.T. Curiel and J.T. Douglas, eds.) **John Wiley & Sons.** 33-62 (2002)
116. K.F. Pirollo, A. Rait, L. Sleer, and E.H. Chang. Antisense Therapeutics: From Theory to Clinical Practice. **Pharmacology and Therapeutics (In Press)**
117. Y. J. Jang, K.F. Pirollo, Z. Hao, Y. Chiang, and E.H. CHANG. Restoration of the G<sub>1</sub> Block and Apoptotic Pathway in SCCA of the Head and Neck by Adenoviral Vector Mediated p53 Gene Therapy. **Submitted to Carcinogenesis.**
118. L. Xu, K.F. Pirollo, W.H. Tang, L.M. Xiang, A. Rait, D. Ulick, W.A. Alexander and E.H. CHANG. Systemic P53 Gene Therapy Using a Tumor-Targeted Adenoviral Vector Results in Radio/Chemo Sensitization and Long-Term Tumor Regression. **Submitted to Science.**
119. A. Rait, K.F. Pirollo , L. Xu, V. Rait, L. Xiang and E.H. CHANG, Antisense HER-2 Oligonucleotides Sensitize Human Breast Cancer to Taxotere *In Vitro* and *In Vivo*. **Submitted to Human Gene Therapy.**
120. K B. Bouker, K.F. Pirollo and E.H. CHANG, p53: Culprit or Bystander in the Treatment Failure of Radio/Chemotherapy. **Submitted to JNCI.**



121. M.S. Jhaveri, A.S. Rait, J.B. Trepel, **E.H. CHANG**. Antisense oligonucleotides targeted to the human alpha folate receptor sensitize breast cancer cells to doxorubicin treatment *in vitro*. Submitted to **Molecular Cancer Therapeutics**.

#### THESIS AND DISSERTATION

1. **E. H. CHANG**. Adaptation of Grace's continuous lines of insect cells to medium containing heterologous serum. Bachelor's Thesis (U.S. Naval Medical Research Unit No. 2, Fu Jen University, Taipei, Taiwan (1968).
2. **E. H. CHANG**. Comparative studies of growth patterns of Ganjam Virus in CE, BHK and VERO and *Aedes albopictus* cells. Ph.D. Dissertation, Southern Illinois University, Carbondale, Illinois (1974).

#### PATENT - APPLICATION FILED

1. c-Raf Transgenic Non-Human Mammals.
2. An Automated Method for the Detection of p53 Mutations.
3. Treatment of Tumors by a Combination of Radiation Therapy and Transduction with Polynucleotide Encoding Wild Type p53.
4. Method of Reversal of Resistance to Radiation Therapy and to Chemotherapy in Cancer Cells Using Sequence-Specific Anti-HER-2 Oligonucleotides.
5. Modified Antisense Nucleotides Complementary to a Section of the Human Ha-ras Gene.
6. Targeted Liposome Gene Delivery.
7. Compositions and Methods for Reducing Radiation and Drug Resistance in Cells.
8. Systemic Viral/Ligand Gene Delivery System and Gene Therapy.
9. Ligand-PEG "Post-coated" Cationic Liposomes for Targeted Gene Delivery.
10. Antibody Fragment-Targeted Immunoliposomes for Systemic Gene Delivery.
11. A Simplified and Improved Method for Complexing an Antibody Fragment-Targeted Immunoliposome for Systemic Gene Delivery.

## RESEARCH GRANTS

Esther H. Chang, Ph.D.

### 1. Currently Active Support:

1. National Institutes of Health, A Novel Improvement on Radiotherapy for SCCHN  
P.I. 20% Effort on Project  
Project Period: 1 APRIL 1999-31 MARCH 2003  
Total: \$286,320
2. Natl. Foundation for Cancer Research, Chemosensitization of Breast Cancer by Systemic Delivery of Anti-HER2 Oligonucleotides  
P.I. 5% Effort on Project  
Project Period: 1 OCTOBER 2000- 30 SEPTEMBER 2003  
Total: \$130,435
3. NIH STTR Phase I Application 1R41 CA91660-01A1. Targeting Stealth™ Liposome for Cancer Gene Therapy.  
Jointly with SynerGene Therapeutics, Inc  
10% Effort on Project  
Requested project period: 1 JUNE 2002 – 31 MAY 2003  
Total Requested: \$41,143 (Georgetown portion).
4. NIH STTR Phase II Application 2R42 CA80449-2A1 Immunoliposome-Mediated Gene Therapy for Prostate Cancer.  
Jointly with SynerGene Therapeutics, Inc.  
20% effort on project.  
Requested Project Period: 1 SEPTEMBER 2002 – 31 AUGUST 2004  
Total Requested: \$169,280 (Georgetown University Portion).
5. NCI, decision Network Program, Transferrin-Liposome (Synerlip) Mediated Systemic Gene Delivery for Human Prostate Cancer.  
P.I.  
Project Period: February 1999-  
The Decision Network has chosen our transferrin-lioposome-p53 complex (Synerlipp53) for further development and testing in Phase I clinical trials by the NCI.
6. NCI, Rapid Access to Intervention Development (RAID) Program, Tumor-Specific Targeting of wtp53 by Anti-Transferrin Receptor Single Chain Antibody: A New Therapeutic Strategy for Prostate Cancer Treatment  
P.I.  
Project Period: 1 APRIL 1999-  
The RAID program does not supply funds to the approved projects. The RAID is designed to accomplish tasks that are rate-limiting in bringing discoveries from the laboratory to the clinic. Thus, in support of this project the RAID program is producing, through the use of NCI's development contracts, GLP/GMP grade reagents including the TfRscFv, the liposome and the wtp53 expression plasmid.

### 2. Past Support:

1. USUHS, Regulation of the Expression of Human c-ras Genes.  
1 OCTOBER 1982 - 30 SEPTEMBER 1985.  
\$60,000 - 3 years. P.I. 10%
2. USUHS, Molecular Cloning of a Tumor Oncogene in a Cancer-Prone Family.  
1 OCTOBER 1985 - 30 SEPTEMBER 1989.  
\$154,125 - 4 years. P.I. 10%
3. NIH, Oncogenes (c-ras) in Human Cancer Induction.  
1 MAY 1983 - 30 APRIL 1986.  
\$160,000 - 3 years. P.I. 40%
4. Medical Applications of Advanced Laser Technology (MAALT). Probing the Molecular Mechanisms of Carcinogenesis.

- 1 JANUARY 1986 - 31 DECEMBER 1988.  
\$150,000 - 3 years. P.I. 10%
5. NIH, Oncogenes in Human Cancer Induction.  
1 SEPTEMBER 1986 - 31 DECEMBER 1989.  
\$258,791 - 3 years. P.I. 40%
  6. NIH, a program project. Subproject III. Modulation of Tumor Cell Growth. Program project P.I. Paul O. P. T'so, Johns Hopkins University. Program project. Title: Oligonucleotide Analogs as Antiviral/Anticancer Agents.  
1 AUGUST 1986 - 31 DECEMBER 1989.  
\$145,190 - 3 years. Co-P.I. 15%
  7. Medical Applications of Advanced Laser Technology (MAALT). Experimental Therapy of Human Colorectal Tumors.  
1 JANUARY 1989 - 31 DECEMBER 1990.  
\$80,000 - 3 years. P.I. 10%
  8. NIH, Modulation of Tumor Growth in vitro and in vivo.  
1 JULY 1990 - 30 JUNE 1995.  
\$649,018 - 5 years. P.I. 15%
  9. NIH, Oncogenes in Human Cancer Induction.  
1 DECEMBER 1989 - 30 NOVEMBER 1994.  
\$757,798 - 5 years. P.I. 25%
  10. USUHS, Inherited Genetic Defects in Li-Fraumeni Syndrome.  
1 OCTOBER 1992 - 30 SEPTEMBER 1995.  
\$81,000 - 3 years. Co-P.I. 5%
  11. Naval Medical Research and Development Command. Demonstration of Cytokines and Growth Factors in Wound Healing.  
1 APRIL 1991 - 30 SEPTEMBER 1996  
\$485,400 - 5.5 years P.I. 5%
  12. National Foundation for Cancer Research, HU0001, Modulation of the Radiation-Resistant Phenotypes of Tumor Cells by Sequence-Specific Oligonucleotides.  
1 OCTOBER 1988 - 30 SEPTEMBER 1999  
\$638,750-9 years P.I. 10%
  13. NIH, CA45158, The Status of Suppressor Genes in a Cancer-Prone Family.  
1 DECEMBER 1994 - 30 NOVEMBER 1999  
\$1,003,887 - 5 years P.I. 30%
  14. Genetic Therapy Inc./NOVARTIS, Sensitization of Tumors to Radiation Therapy by Restoration of the G1 Checkpoint.  
1 OCTOBER 1997 - 30 SEPTEMBER 1998  
\$60,000-1 year P.I. 5%
  15. NIH STTR Phase I Application 1 RA1 CA80449-01. Immunoliposome-Mediated Gene Therapy for Prostate Cancer.  
(Jointly with SynerGene Therapeutics, Inc.)  
1 NOVEMBER 1998 - 31 OCTOBER, 1999  
\$57,600 (Georgetown University Portion) 1 year, P.I. 10%
  16. NIH, 5D50 CA58185-06, SPORE in Breast Cancer (Marc E. Lippman, P.I.).  
Development Project, p53 Mediated, Tumor-Targeted Sensitization to Chemotherapy and Radiotherapy.  
1 SEPTEMBER 1997 - 31 AUGUST 2001  
\$50,000- 4 year P.I. 10%
  - 17.DOD Concept Award, Systemic Apoptin Gene Therapy for Chemo/Radiosensitization of Breast Cancer  
1 SEPTEMBER 2000-31 AUGUST 2001

\$50,000- 1 year P.I. 5%

### 3. Pending Support

1. NIH RO1 Application. Non-Invasive Methods to Assess p53 Gene Therapy Effects.

Submitted on February 1, 2001

15% effort on project

Request Project Period:

1 DECEMBER 2001 – 30 NOVEMBER 2005

Total Requested:

\$1,513,200

2. NIH RO1 Application. Surrogate End-Points to Assess p53 Therapy in SCCHN.

Submitted on June 1, 2001

10% effort on project (CO-PI)

Requested Project Period:

1 April, 2002 – 31 March, 2006

Total Requested:

\$1,496,640

3. NIH RO1 Application. Systematic Sensitization of Pancreatic Cancer to Gemzar

Submitted on February 1, 2002

20% effort on project

Requested Project Period:

1 December 2002 – 30 November 2006

Total Requested:

\$1,864,810

# A New Reagent Which May Be Used to Introduce Sulphydryl Groups into Proteins, and Its Use in the Preparation of Conjugates for Immunoassay

R. JULIAN S. DUNCAN, PETER D. WESTON, AND ROGER WRIGGLESWORTH

The Wellcome Research Laboratories, Langley Court, Beckenham, Kent. BR3 3BS, United Kingdom

Received December 1, 1982

A synthesis of the *N*-hydroxysuccinimide ester of *S*-acetylthioacetic acid is described. This material is stable when stored dry and has advantages over the currently available reagents used to introduce sulphydryl groups into a variety of proteins. Proteins modified with this reagent can be used to prepare conjugates for enzyme immunoassay. The conjugation techniques described cause little or no loss of either enzyme activity or antibody titer and function, and the conjugates contain little polymeric material.

Sulphydryl-maleimide coupling is a technique for the preparation of protein to protein conjugates which occurs through very stable amide and thioether bonds with the necessary modification reactions usually causing very little disruption to the functions of the proteins (reviewed by Ishikawa (1)). Proteins to be conjugated must have at least one functionally unessential sulphydryl group; otherwise it is necessary to incorporate such a group into the molecule before conjugation is possible. There are three methods commonly used to achieve this: by reaction with *N*-succinimidyl 3-(2-pyridyldithio)propionate (SPDP; from Pharmacia), with methyl 4-mercaptobutyrimidate in the presence of 4,4'-dithiodipyridine (2), or with SAMSA<sup>1</sup> (3). Each of these methods introduces a sulphydryl group protected from adventitious reaction, particularly oxidation, so that the substituted protein may be stored for long periods. Use of SAMSA has an advantage over the other methods in that deprotection is with hydroxylamine, rather than with excess of another thiol which has to be scrupulously removed

before proceeding with the conjugation. SAMSA, the reagent described in this communication, has this advantage of SAMSA and two further. First, the electrostatic charge of the modified protein is less disturbed (loss of one positive charge per sulphydryl inserted compared with the loss of a positive and gain of a negative). Second, only one form of derivative can be formed with SAMSA whereas the linking amide bond may be with either of the carboxyl functions of SAMSA, leading to problems in characterization of conjugates of small molecules and peptides.

## MATERIALS

Succinimidyl 4-(*N*-maleimidomethyl)-cyclohexane-1-carboxylate was a gift from Dr. Ishikawa, or was obtained from Pierce-Warriner (Chester, U. K.). Horseradish peroxidase was Type VI from Sigma (London) Ltd., and had an *R<sub>i</sub>* (4) of about 3. Thiopropyl Sepharose 6B and Sephacryl S-300 were from Pharmacia. Organic solvents were distilled and then stored over a Fisher Molecular Sieves Type 4A, to ensure dryness. IgG was purified from sheep serum by salt fractionation and chromatography on DEAE-cellulose. Other chemicals were from BDH Poole (Dorset, U. K.) or Sigma (London) Ltd.

<sup>1</sup> Abbreviations used: SAMSA, *S*-acetylmercaptosuccinic anhydride; SATA, *N*-succinimidyl *S*-acetylthioacetate; IgG, Immunoglobulin G.

0003-2697/83 \$3.00

Copyright © 1983 by Academic Press, Inc.  
All rights of reproduction in any form reserved.

## METHODS A

*Synthesis of S-*  
shown in Fi  
58 g, 0.02 m  
the method  
dry dichlor  
hydroxysuccin  
of dichloro  
temperature f  
imide (4.15  
methane wa  
was stirred  
The preci  
g) was remo  
evaporated,  
me (50 ml).  
covery of the  
the filtrate e  
which crystallize  
was recrystallized  
SATA (3.11  
for disk) 182  
2.40 (S,  
succinimidyl-; 3.  
C, 41.41  
S requir  
%).  
NMR spec  
approximately 2.5  
about 10%  
succinimide  
decomposition  
matography  
and by si  
type show  
Reaction c  
to be all  
in 50 m  
pH 7.5, o  
use, SAT  
up to 15  
added to th



FIG. 1

## METHODS AND RESULTS

(a) *Synthesis of SATA.* The structure of SATA is shown in Fig. 1. *S*-acetylthioacetic acid (2.68 g, 0.02 mol), made in 48% yield following the method of Benary (5), was dissolved in dry dichloromethane (5 ml), mixed with *N*-hydroxysuccinimide (2.30 g, 0.02 mol) in 30 ml of dichloromethane, and stirred at room temperature for 10 min. Dicyclohexylcarbodiimide (4.15 g, 0.02 mol) in 2 ml of dichloromethane was added and the reaction mixture was stirred for 18 h at room temperature. The precipitated dicyclohexylurea (4.024 g) was removed by filtration and the filtrate evaporated, then stirred with dichloromethane (50 ml). Residual urea (0.484 g; total recovery of the urea = 100%) was filtered off and the filtrate evaporated to give a yellow oil which crystallized on trituration with ether. The solid was recrystallized from 2-propanol to give SATA (3.162 g, 68%), mp 85–86°C:  $\nu_{\text{max}}$  (KBr disk) 1825, 1787, 1740, 1695  $\text{cm}^{-1}$ ;  $\delta$  ( $\text{CDCl}_3$ ) 2.40 (s, 3H),  $\text{CH}_3\text{CO}$ ; 2.77 (s, 4H) succinimidyl-; 3.93 (s, 2H)  $-\text{S}-\text{CH}_2\text{CO}-$ . (Found C, 41.41%; H, 3.84%, N, 5.70%;  $\text{C}_8\text{H}_{10}\text{NO}_4\text{S}$  requires C, 41.56%; H, 3.90%; N, 6.06%).

The NMR spectrum of material stored for approximately 2.5 years at 4°C over silica gel showed about 10% decomposition to give *N*-hydroxysuccinimide. Further evidence of this slight decomposition is given by thin-layer chromatography using methyl ethyl ketone as solvent, and by small shifts in titration curves of the type shown in Fig. 2.

(b) *Reaction of SATA with proteins.* The protein to be alkylated with SATA was dissolved in 50 mM sodium–potassium phosphate, pH 7.5, containing 1 mM EDTA. Just before use, SATA was dissolved at concentrations up to 150 mM in dimethylformamide and added to the solution of protein at room

temperature with the concentrations adjusted so that less than 10  $\mu\text{l}$  of organic solvent were added/ml of aqueous solution. The reaction between 65  $\mu\text{M}$  IgG and 520  $\mu\text{M}$  SATA is complete within 10 min as may be shown by stopping the reaction (by the addition of Tris-HCl, pH 7.8, to 60 mM) at various times after mixing the reactants and measuring the extent of *S*-acetylthioacetylation of the protein. After derivatization the protein was separated from small molecules by gel filtration into the phosphate-EDTA, and was stored either at 4°C or frozen.

Particular proteins are *S*-acetylthioacetylated by SATA to an extent which depends on the concentrations of both reactants, and the relationship between these variables for certain proteins is shown in Fig. 2 and Table 1. The graph shown for IgG in Fig. 2 was obtained with IgG from sheep serum, but an identical relationship was found for a number of conventional and monoclonal IgG preparations. The effect of SATA treatment on the functional capability of an antibody was investigated using the mutant  $\beta$ -galactosidase-activating antibody system (6) which allows direct measurement of both the binding constant and stoichiometry of the antibody–enzyme reaction in solution. It was found that incorporation of up to a mean of at least 6 mol of *S*-acetylthioacetate/mol of IgG had no discernible effect on either of these constants, or on the extent of activation of the enzyme. Hence incorporation of this reagent into an antibody has little effect on its function. In six separate reactions of 65  $\mu\text{M}$  IgG with 2.5 mol of SATA/mol of IgG an incorporation of a mean of  $1.18 \pm 0.06$  (SEM) mol of sulfhydryl/mol of IgG was found after deacetylation (see below), and  $24 \pm 1.2\%$  of the protein then failed to bind to activated thiopropyl Sepharose 6B during chromatography following the general method of Brocklehurst *et al.* (7). There was an unmeasurably low level of sulfhydryl in the unbound protein. (The concentration of unbound protein was measured after gel filtration to obviate interference from 2-mercaptopyridine from the column.)




FIG. 1. The structure of SATA.

## Conjugates for Immunoassay

GER WRIGGLESWORTH

ent. BR3 3BS, United Kingdom


icetic acid is described. This reagently available reagents used modified with this reagent can conjugation techniques described function, and the conjugates

eding with the conjugation. eagent described in this comas this advantage of SAMSA and First, the electrostatic charge of protein is less disturbed (loss of charge per sulfhydryl inserted. h the loss of a positive and gain ). Second, only one form of do be formed with SATA whereas nide bond may be with either of functions of SAMSA, leading to characterization of conjugates dles and peptides.

## MATERIALS

yl 4-(*N*-maleimidomethyl)- $\alpha$ -carboxylate was a gift from Dr. was obtained from Pierce-War; U. K.). Horseradish peroxidase, from Sigma (London) Ltd., and 4) of about 3. Thiopropyl Sep and Sephacryl S-300 were from rganic solvents were distilled and over a Fisher Molecular Sieve, ensure dryness. IgG was purified serum by salt fractionation and phy on DEAE-cellulose. Other ere from BDH Poole (Dorset, ima (London) Ltd.





of proteins. The mole ratios of 0  $\mu$ M peroxidase;  $\bullet$ , 62.5  $\mu$ M is described in the text.

0  $\mu$ l of this solution for each reaction to be deacetylated (8), was more than 90% exposed at room temperature and then range in the sulfhydryl concentration the next 24 h when the solution stopped at 4°C. Sulfhydryl using Ellman's reagent (9) or line (10) for solutions of

on of conjugates and their

Reactive maleimide substituted into one of the proteins, usually IgG, by treatment with N-maleimido-succinimide (11), and the reaction was measured by back-titration with 2-mercaptoethanol and Ellman's reagent. A titration curve similar to that obtained for the selection of the reagent required for a given degree of substitution of the conjugates described by the mole ratios of peroxidase to IgG except as noted.

The IgG derivative was added over about 0.5 h to SATA-treated peroxidase (containing a mean of about 1 mol of sulfhydryl/mol of protein) that had been deacetylated previously. After 1–2 h at room temperature the reaction was stopped by addition of 2-mercaptoethanol to twice the original maleimide concentration and then, 15 min later, N-ethylmaleimide to twice the total sulfhydryl concentration. The ratio of peroxidase to IgG in the conjugates was calculated approximately from a knowledge of the absorbance of the conjugates at 403 and 280 nm and the  $R_e$  of peroxidase and it was found that the composition of the conjugate could be varied by changing the ratio of IgG and enzyme allowed to react or by varying the degree of maleimide substitution of the IgG. At a final IgG concentration of 20  $\mu$ M, reaction of 12 nmol of the IgG with 38 or 200 nmol of monothiolated peroxidase resulted in conjugates containing a mean of 1.5 or 2.5 mol of enzyme/mol of IgG, respectively. Reaction of 20 nmol of IgG containing 9 mol maleimide/mol with 180 nmol of peroxidase yielded conjugates containing 5.4 mol of enzyme/mol of IgG.

The chromatographic and electrophoretic characteristics of a conjugate of IgG and peroxidase (350 nmol of peroxidase reacted with 110 nmol of IgG) are shown in Figs. 3 and 4. It can be seen that the conjugate was separated clearly from the excess of enzyme by chromatography on Sephacryl S-300. Electrophoresis of the pooled conjugate of Fig. 3 on polyacrylamide gels in the pH 2.4 system of DeJbler *et al.* (12) (Fig. 4) shows that the conjugate is polydisperse but, unlike the conjugate prepared by periodate oxidation of peroxidase (13) and shown for comparison, has little high molecular weight material near the starting point of the gel, and no unlabeled IgG.

## DISCUSSION

Our chief applications for SATA have been for the conjugation of an enzyme, usually peroxidase but on occasions urease, to IgG for use in enzyme immunoassay and for the conjugation of peptide hormones. For these applications it is important to minimize the formation of polymeric products so as to conserve the effective titer of the antibody and reduce nonspecific interactions. In order to




FIG. 3. Chromatography of an IgG-peroxidase conjugate. Conjugate (6 ml) was chromatographed on Sephacryl S-300 (95  $\times$  0.8 cm<sup>2</sup>) in 50 mM Tris-HCl, pH 8.0, at a flow rate of 4 cm h<sup>-1</sup>. The effluent was monitored at 280 and 403 nm, and the ratio of peroxidase to IgG in the eluate is shown by the upper broken curve. Elution volume increases toward the right.






FIG. 4. Electrophoresis of IgG-peroxidase conjugates. About 30  $\mu$ g of peroxidase conjugates ((A) from Fig. 3; (B) prepared by the Nakane and Kawaoi (13) technique) was electrophoresed for 10 mA  $\cdot$  h/gel at pH 2.4 (12). The gels were stained with Coomassie blue R-250 then scanned at 595 nm. IgG runs to the point marked with an arrowhead. The top of the gel (anodic) is to the right.

ensure complete lack of polymer formation during conjugation, one of the proteins must bear only a single substituent. It would be expected that the reaction of SATA with IgG would give a distribution of alkylated molecules which is approximately Poisson in form: for IgG substituted with a mean of 1.18 mol of sulfhydryl/mol (as described in (b) above) a Poisson distribution would encompass some 36% of the molecules being monosubstituted, 33% having more than one substituent, and 31% being unsubstituted; this prediction is in reasonable agreement with the 24% found unsubstituted by experiment. Hence, single substitution can be obtained with only a small fraction of IgG molecules, and this is probably true for most proteins. Even with horseradish peroxidase in which very few amino groups are available for substitution ((14) and Fig. 2) multiple substitution would be expected in a

significant proportion of the molecules. Nevertheless it is apparent that fewer potential polymerization sites will result if the single active group mentioned above is inserted into the peroxidase rather than the IgG. With this in mind we attempted to minimize the problem of polymer formation by slowly adding the IgG, substituted with 4 mol of maleimide/mol, to a calculated molar excess of enzyme molecules bearing a mean of one substituent group. As can be seen from Fig. 4, this procedure is effective if the conjugation reaction is stopped after about 2 h. Conjugates prepared by this technique contain no unlabelled IgG, as may be seen from Fig. 4 and also by chromatography of conjugates of peroxidase on immobilized concanavalin A when no antibody is eluted before the enzyme. We have found that it is unnecessary to do more than dialyze the conjugation mixtures directly after

stopping the reaction in order to prepare a variety of enzyme. The synthesis of it and gives a good yield. Use of SATA is also: reproducible modification of proteins under mild conditions without loss of activity or function.

#### ACKNOWLEDGMENTS

We thank Dr. Shireen Khatib for discussion and in their ELISA systems.

#### REFERENCES

1. Ishikawa, E. (1980).
2. King, T. P., and Kohn, J. (1978). *Anal. Methods*, 28, 1-10.




Fig. 4. Electrophoresis of peroxidase conjugates ((A) from) electrophoresed for 10 mA · h/gel at scanned at 595 nm. IgG runs to the right.

proportion of the molecules. Now it is apparent that fewer potential binding sites will result if the single binding site mentioned above is inserted into the enzyme rather than the IgG. With this in mind, we attempted to minimize the polymer formation by slowly adding the enzyme to the conjugate substituted with 4 mol of maleimide. The calculated molar excess of enzyme bearing a mean of one substituent can be seen from Fig. 4, this procedure is effective if the conjugation reaction is allowed to proceed for about 2 h. Conjugates prepared by this technique contain no unlabeled enzyme. This can be seen from Fig. 4 and also by the electrophoresis of conjugates of peroxidase substituted with concanavalin A when no enzyme was added before the enzyme. We have found that it is unnecessary to do more than to add the conjugation mixtures directly after

stopping the reactions with *N*-ethylmaleimide in order to prepare products satisfactory for a variety of enzyme immunoassays.

The synthesis of this ester, SATA, is simple and gives a good yield of a stable product. Use of SATA is also straightforward and gives reproducible modification of a variety of proteins under mild conditions, with little loss of the activity or function of the protein.

#### ACKNOWLEDGMENTS

We thank Dr. Shireen M. Chantler and Mr. E. Krambovitis for discussion and for evaluation of our conjugates in their ELISA systems.

#### REFERENCES

1. Ishikawa, E. (1980). *Immunoassay*, Suppl. 1, 1-16.
2. King, T. P., and Kochoumian, L. (1979). *J. Immunol. Methods*, 28, 201-210.
3. Weston, P. D., Devries, J. A., and Wrigglesworth, R. (1980). *Biochim. Biophys. Acta* 612, 40-49.
4. Theodrell, H., and Maehly, A. C. (1950). *Acta Chem. Scand.* 4, 422-434.
5. Benary, E. (1913). *Ber. Dtsch. Chem. Ges.* 46, 2103-2107.
6. Duncan, R. J. S., Hewitt, J., and Weston, P. D. (1982). *Biochem. J.* 205, 219-224.
7. Brocklehurst, K., Carlsson, J., Kierstan, M. P. J., and Crook, E. M. (1973). *Biochem. J.* 133, 573-584.
8. Klotz, I. M., and Heinley, R. E. (1962). *Arch. Biochem. Biophys.* 96, 605-612.
9. Ellman, G. L. (1959). *Arch. Biochem. Biophys.* 82, 70-77.
10. Grassetti, D. R., and Murray, J. F. (1967). *Arch. Biochem. Biophys.* 119, 41-49.
11. Yoshitake, S., Yamada, Y., Ishikawa, E., and Masseyeff, R. (1979). *Eur. J. Biochem.* 101, 395-399.
12. Deibler, G. E., Martenson, R. E., and Kies, M. W. (1972). *Prep. Biochem.* 2, 139-165.
13. Nakane, P. K., and Kawaoi, A. (1974). *J. Histochem. Cytochem.* 22, 1084-1091.
14. Klapper, M. H., and Hackett, D. P. (1965). *Biochim. Biophys. Acta* 95, 272-282.

## A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells

Theresa M. Allen <sup>a,\*</sup>, Ester Brandeis <sup>b</sup>, Christian B. Hansen <sup>a</sup>, Grace Y. Kao <sup>a</sup>,  
Samuel Zalipsky <sup>b</sup>

<sup>a</sup> Department of Pharmacology, University of Alberta, Edmonton, AB, T6G 2H7, Canada

<sup>b</sup> Liposome Technology Inc., 1050 Hamilton Court, Menlo Park, CA 94025, USA

Received 21 October 1994; revised 8 March 1995; accepted 10 March 1995

### Abstract

The development of long-circulating formulations of liposomes (S-liposomes), sterically stabilized with lipid derivatives of poly(ethylene glycol) (PEG), has increased the likelihood that these liposomes, coupled to targeting ligands such as antibodies, could be used as drug carriers to deliver therapeutic drugs to specific target cell populations *in vivo*. We have developed a new methodology for attaching monoclonal antibodies to the terminus of PEG on S-liposomes. A new end-group functionalized PEG-lipid derivative pyridylthiopropionoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) was synthesized for this purpose. Incorporation of PDP-PEG-DSPE into S-liposomes followed by mild thiolysis of the PDP groups resulted in formation of reactive thiol groups at the periphery of the lipid vesicles. Efficient attachment of maleimide-derivatized antibodies took place under mild conditions even when the content of the functionalized PEG-lipid in S-liposomes was below 1% of total lipid. The resulting S-immunoliposomes showed efficient drug remote loading, slow drug release rates and increased survival times in circulation compared to liposomes lacking PEG. When antibodies recognizing several different tumor-associated antigens were coupled to the PEG terminus of S-liposomes, a significant increase in the *in vitro* binding of liposomes to the target cells was observed. The binding of S-immunoliposomes containing entrapped doxorubicin to their target cell population resulted in increased cytotoxicity compared to liposomes lacking the targeting antibody.

**Keywords:** Sterically stabilized liposome; Poly(ethylene glycol); Liposome targeting; Doxorubicin; Immunoliposome; Selective toxicity; Toxicity

### 1. Introduction

Site-specific delivery of drugs to diseased cells can lead to significant reductions in drug toxicity, and increased therapeutic effects. Therapeutic applications of liposomal drug delivery systems have been extensively explored in recent years [1–5], and several methods have been developed for attachment of antibodies (Ab) at the liposome surface [6–9] in attempts to target the liposomes *in vivo* to specific sites of drug actions. Attachment of Ab at the surface of classical formulations of liposomes results in their rapid removal from circulation by the cells of the mononuclear phagocyte system (MPS, also termed reticuloendothelial system) [10,11]. New formulations of sterically stabilized liposomes (SL) have been developed recently which have extended blood circulation times as a result of reduced rates and extents of uptake by MPS cells [12–15]. SL contain, as the key component, methoxy poly(ethylene glycol) distearoylphosphatidylethanolamine

**Abbreviations:** mPEG, methoxy poly(ethylene glycol); MPS, mononuclear phagocyte system; SL, sterically stabilized (Stalith<sup>®</sup>) liposomes; mPEG-DSPE, methoxy poly(ethylene glycol) distearoylphosphatidylethanolamine; PDP-PEG-DSPE, pyridylthiopropionoylamino poly(ethylene glycol) distearoylphosphatidylethanolamine; SIL, sterically stabilized immunoliposomes; DSPE, distearoylphosphatidylethanolamine; SPDP, *N*-succinimidyl-3-(2-pyridylthio)propionate; DSC, disuccinimidylcarbonate; SC, succinimidylcarbonate; Boc, *tert*-butoxycarbonyl; TLC, thin-layer chromatography; TEA, triethylamine; PDP, pyridylthiopropionate; HSPC, hydrogenated soy phosphatidylcholine; SMPB, succinimidyl-4-(*p*-maleimidophenyl)butyrate; MPB-PE, maleimido phenylbutyrate phosphatidylethanolamine; <sup>3</sup>H-CHE, [<sup>3</sup>H]cholesteryl hexadecyl ether; [<sup>125</sup>I]-TI, [<sup>125</sup>I]tyraminyl inulin; Ab, polyclonal antibody; mAb, monoclonal antibody; Hepes, *N*-(2-hydroxyethyl)piperazine-*N'*-(2-ethanesulfonic acid); Mes, 2-(*N*-morpholino)ethanesulfonic acid; CHOL, cholesterol; DTT, dithiothreitol; DXR, doxorubicin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; KLN 205, murine squamous lung carcinoma; Caov-3, human ovarian adenocarcinoma; HCT-15, human colon adenocarcinoma; mAb 174H.64, antibody recognizing KLN 205; mAb B43.13, antibody recognizing Caov-3; mAb M170, antibody recognizing HCT-15.

\* Corresponding author. Fax: +1 (403) 4924325.

(mPEG-DSPE) (4–8 mol% of the total lipid). This results in coverage of the lipid vesicle surfaces with grafted amphipathic polymer chains. It is believed that the high mobility of the mPEG chains, associated with their conformational flexibility, and also their water-binding ability, contribute to the steric stabilization which is responsible for their prolonged survival times in circulation [16,17].

We were interested in developing methods for attachment of Ab to the surface of SL which would meet a number of important criteria for 'ideal immunoliposomes'. These include: simplicity and ease of preparation, maintenance of prolonged circulation half-lives, retention of target recognition for the Ab, high coupling efficiency of the Ab to the liposomes, the ability to achieve high Ab densities at the liposome surface, the ability to achieve efficient drug remote loading, appropriate drug release characteristics, and compatibility with use in humans.

Attachment of Ab at the surface of SL, in the phospholipid headgroup region, can result in some decrease in coupling efficiency and some loss of Ab recognition, particularly in the presence of high molecular weights of mPEG which can sterically hinder access of the Ab to the liposome surface during coupling procedures and/or access of the Ab binding region to its epitope after its attachment to the liposomes [8,18,19]. Because some of the antibody coupling methods in the literature fell considerably short of the ideal, when applied to SL, we have developed a new coupling method, specifically for use with SL, which forms *S*-immunoliposomes (SIL) by covalently coupling antibodies to the liposomes via a thioether bond at the PEG terminus (Fig. 1), rather than to the phospholipid headgroup region on the liposome surface. This new method comes close to meeting the criteria outlined above for ideal SIL. Attachment of proteins to the distal end of PEG terminus using a PEG-COOH construct has recently been described by two different groups, with retention of long-circulating half-lives and target binding [20,21].

## 2. Materials and methods

### 2.1. Materials

Distearoylphosphatidylethanolamine (DSPE) was purchased from Sygena, Cambridge, MA, disuccinimidylcarbonate (DSC) from Fluka (Ronkonkoma, NY), and *N*-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) from Bioaffinity Systems (Rosco, IL). Heterobifunctional  $\alpha$ -amino- $\omega$ -hydroxy-PEG was prepared by partial conversion of hydroxy end groups of PEG-2000 (Fluka) into primary amines [22], followed by ion-exchange purification according to Furukawa [23]. Amino-PEG-DSPE was prepared as described elsewhere [24].

Hydrogenated soy phosphatidylcholine (HSPC) and methoxy (polyethylene glycol) (2000) distearoylphos-




Fig. 1. Schematic diagram of the coupling of a maleimide-activated antibody (MPB-Ab) with sterically stabilized liposomes containing PDP-PEG-DSPE.

phatidylethanolamine (mPEG-DSPE) were obtained from Liposome Technology (Menlo Park, CA). mPEG-DSPE synthesis was described in [14]. Cholesterol (CHOL) and pyridyldithiopropionate dioleoylPE (PDP-DOPE) were purchased from Avanti Polar Lipids (Birmingham, AL). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT); *N*-succinimidyl-4-(*p*-maleimidophenyl)-butyrate (SMPB) and sheep IgG, used as a source of antibody (Ab) were purchased from Sigma (St. Louis, MO). Doxorubicin was obtained from Adria Laboratories (Mississauga, Ontario).  $\text{Na}^{125}\text{I}$  and cholesterol [1,2(n)- $^3\text{H}$ ]hexadecyl ether, 1.48–2.22 TBq/mmol ( $^3\text{H}$ -CHE) was purchased from New England Nuclear (Mississauga, Ontario). Tyraminylinulin was synthesized and [ $^{125}\text{I}$ ]tyraminylinulin ( $^{125}\text{I}$ -TI) was prepared as previously described [25]. Iodobeads were purchased from Pierce (Rockford, IL). Monoclonal antibodies (mAb) 174H.64, B43.13 and M170 and the cell lines KLN 205 and Caov-3 were generous gifts of Biomira, Edmonton, AB. The cell line HCT-15 was purchased from American Type Culture Collection (Rockville, MD). All other chemicals were analytical grade.

### 2.2. Synthesis

#### General methods

TLC on silica gel G were visualized with iodine vapour, ninhydrin and Dragendorff [26] spray reagents, when ap-

appropriate. NMR spectra was recorded on a 360 MHz Nicolet instrument. When it was important to detect the terminal OH group of PEG, DMSO- $d_6$  was used as a solvent [27], otherwise  $CDCl_3$  was used.

#### Preparation of PDP-PEG-OH

SPDP (100 mg, 0.32 mmol) and  $\alpha$ -amino- $\omega$ -hydroxy-PEG (0.55 g, 0.275 mmol) dissolved in acetonitrile (2 ml) reacted at 25°C for 4 h. TLC of the reaction mixture ( $CHCl_3/CH_3OH$ , 8:2) showed disappearance of  $H_2N$ -PEG-OH with appearance of a less polar, UV-absorbing new material ( $R_f = 0.80$ ). The solvent was rotary evaporated and ethyl ether (50 ml) added. After overnight storage at 4°C white solid was collected and dried in vacuo over  $P_2O_5$ . Yield: 0.5 g (90%).

$^1H$ -NMR (DMSO- $d_6$ ):  $\delta \approx 2.5$  ( $CH_2S$ , overlap w/ DMSO), 3.01 (t,  $J = 7$  Hz,  $CH_2C = O$ , 2H), 3.20 (m,  $CH_2NH$ , 2H), 3.51 (s, PEG,  $\approx 18OH$ ), 4.52 (t, HO-PEG, 1H), 7.24 (m, pyr, 1H), 7.76 (m, pyr, 1H), 7.82 (m, pyr, 1H), 7.99 (br m, NH, 1H), 8.45 (m, pyr, 1H) ppm.  $^1H$ -NMR ( $CDCl_3$ ):  $\delta$  2.62 (t,  $J = 7$  Hz,  $CH_2SS$ , 2H), 3.08 (t,  $J = 7$  Hz,  $CH_2C = O$ , 2H), 3.47 (m,  $CH_2N$ , 2H), 3.64 (s, PEG,  $\approx 18OH$ ), 6.78 (br s, NH, 1H), 7.10, (m, pyr, 1H), 7.66 (m, pyr, 2H), 8.49 (m, pyr, 1H) ppm.

#### Preparation of PDP-PEG-SC

Meticulously dried PDP-PEG-OH (0.4 g, 0.18 mmol) was dissolved in acetonitrile (0.5 ml) and treated with DSC (81 mg, 0.31 mmol) and pyridine (62 ml, 0.79 mmol) overnight at 25°C. The product was precipitated with ethyl ether (40 ml) at 4°C, redissolved in ethyl acetate (4 ml) and precipitated with equal volume of ethyl ether at 4°C. The product was collected by filtration and dried in vacuo over  $P_2O_5$ . Yield: 330 mg. (85%).

$^1H$ -NMR (DMSO- $d_6$ ):  $\delta \approx 2.5$  ( $CH_2SS$ , overlap w/ DMSO), 2.81 (s, SC, 4H), 3.01 (t,  $J = 7$  Hz,  $CH_2C = O$ , 2H), 3.20 (m,  $CH_2NH$ , 2H), 3.51 (s, PEG,  $\approx 18OH$ ), 4.45 (t,  $CH_2SC$ , 2H), 7.24 (m, pyr, 1H), 7.8 (m, pyr, 2H), 8.0 (br m, NH, 1H), 8.45 (m, pyr, 1H) ppm.  $^1H$ -NMR ( $CDCl_3$ ):  $\delta$  2.62 (t,  $J = 7$  Hz,  $CH_2SS$ , 2H), 2.83 (s, SC, 4H), 3.09 (t,  $J = 7$  Hz,  $CH_2C = O$ , 2H), 3.44 (m,  $CH_2N$ , 2H), 3.64 (s, PEG,  $\approx 18OH$ ), 4.46 (m,  $CH_2SC$ , 2H), 6.73 (br s, NH, 1H), 7.10, (m, pyr, 1H), 7.66 (m, pyr, 2H), 8.48 (m, pyr, 1H) ppm.

#### Preparation of PDP-PEG-DSPE

**Method A.** DSPE (36 mg, 0.043 mmol) was added to a solution of PDP-PEG-SC (100 mg, 0.042 mmol) in chloroform (1 ml), followed by TEA (33  $\mu$ l, 0.237 mmol). The reaction mixture became clear during incubation at 40°C for 10 min. The solvent was evaporated and replaced with acetonitrile (5 ml). The cloudy solution was kept at 4°C overnight. To remove traces of insoluble DSPE the solution was centrifuged and the clear solution separated. It was then rotary evaporated under reduced pressure, and the

residue was dried in vacuo over  $P_2O_5$ . Yield: 130 mg (quantitative).

**Method B.** To a solution of amino-PEG-DSPE hydrochloride [24] (198 mg, 0.07 mmol) in acetonitrile (2 ml), SPDP (26 mg, 0.085 mmol) was added followed by TEA (30 ml, 0.42 mmol). The solution was stirred overnight. The product (200 mg) in chloroform was loaded onto a silica (11 g) column. It was eluted with a step gradient of  $CH_3OH$  in chloroform (5, 10, 15, and 20%, 100 ml each step). Yield: 106 mg of pure product and 77 mg of a product contaminated with a more polar material ( $R_f = 0.125$ ).

The purified products obtained by both methods were identical.

TLC ( $CHCl_3/CH_3OH/H_2O$  90:10:2)  $R_f = 0.52$ .  $^1H$ -NMR ( $CDCl_3$ ):  $\delta$  0.89 (t,  $J = 6.8$  Hz,  $CH_3$ , 6H), 1.26 (s,  $CH_2$ , 56H), 1.58 (br m,  $CH_2CH_2C = O$ , 4H), 2.28 (2 overlapping t,  $CH_2C = O$ ), 2.62 (t,  $J = 7$  Hz,  $CH_2SS$ , 2H), 3.09 (t,  $J = 7$  Hz,  $CH_2C = O$ , 2H), 3.36 (br m,  $OCH_2CH_2N$ , 2H), 3.44 (m,  $CH_2N$ , 2H), 3.64 (s, PEG,  $\approx 18OH$ ), 3.94 (br m,  $CH_2CH_2OP$ , 2H), 4.17 (dd,  $J = 7.0$ , 12 Hz, glycerol  $CH_2OP$ , 2H), 4.21 (m,  $CH_2O_2CN$ , 2H), 4.39 (dd,  $J = 3.2$ , 12 Hz, glycerol  $CH_2OC = O$ , 2H), 5.20 (m, CH, 1H), 6.73 (br, NH, 1H), 7.10, (m, pyr, 1H), 7.66 (m, pyr, 2H), 8.48 (m, pyr, 1H) ppm.  $^{13}C$ -NMR ( $CDCl_3$ ):  $\delta$  14.0 ( $CH_3$ ), 22.7 ( $CH_2CH_3$ ), 24.9 ( $CH_2CH_2C = O$ ), 29.7 ( $CH_2CH_2CH_2$ ), 31.9 ( $CH_2CH_2CH_3$ ), 34.1 and 34.3 ( $CH_2C = O$ ), 34.7 ( $SCH_2CH_2C = O$ ), 35.6 ( $SCH_2CH_2C = O$ ), 39.4 ( $CH_2NHC = O$ ), 42.4 ( $CH_2NHCO_2$ ), 62.8 ( $CH_2OC = O$ ), 63.4 ( $CH_2OPO_3$ ), 64.2 ( $CH_2OC = ON$ ), 69.9 ( $CHOC = O$ ), 70.6 (PEG), 120.0 (C2 pyr), 137.0 (C3 pyr), 120.8 (C4 pyr), 149.7 (C5 pyr), 156.6 (C = O of urethane), 159.8 (C1 pyr), 170.7 (C = O of amide), 173.0 and 173.3 (C = O of esters) ppm.

#### 2.3. Preparation of immunoliposomes

##### Liposome preparation

Liposomes were prepared by hydrating dry lipid films in an appropriate buffer, at a lipid concentration of 10 mM. The resulting multivesicular preparations were then passed through 0.08–0.1  $\mu$ m polycarbonate membranes (Nuclepore, Picasanton, CA or Poretics, Livermore, CA) using a Lipex extruder (Lipex Biomembranes, Vancouver, BC), to give primarily unilamellar vesicles of approx. 100 nm in diameter [28,29]. The resulting liposomes were sized by dynamic light scattering using a Brookhaven B190 particle sizer (Brookhaven Instruments, Holtsville, NY).

##### Iodination of antibody

Ab (2 mg) was dissolved in 200  $\mu$ l of 25 mM Hepes, 140 mM NaCl, pH 7.4 buffer. The Ab solution was mixed with 185 MBq of  $Na^{125}I$  in a 2 ml reaction vial with 5 Iodobeads for 1 h at room temperature (22°C).  $^{125}I$ -Ab was purified by passage over a Sephadex G25 gel filtration column, eluting with the above buffer.

#### Preparation of maleimidophenylbutyrate-Ab (MPB-Ab)

Ab was dissolved in 25 mM Hepes, 140 mM NaCl, pH 7.4 at concentration of 10 mg/ml and trace amounts of  $^{125}\text{I}$ -Ab were added. SMPB (25 mM in dimethylformamide) was slowly added to the Ab solution at a molar ratio of 20:1 (SMPB/Ab) for 30 min at room temperature. Unbound SMPB was removed and the pH lowered by passing the solution over a Sephadex G50 column in 25 mM Hepes, 25 mM Mes, 140 mM NaCl, pH 6.7 buffer.

#### Antibody conjugation

Liposomes were composed of HSPC/CHOL/PDP-PEG-DSPE at a molar ratio of 2:1:0.02 with or without 4 mol% mPEG-DSPE (total PEG lipid, 5 mol% of PL) or of HSPC/CHOL/PDP-DOPE, at a molar ratio of 2:1:0.02 with or without 5 mol% mPEG-DSPE. In experiments to determine the coupling efficiency of the PDP-PEG-PE method, the ratio of PDP-PEG-DSPE and mPEG-DSPE were varied, keeping the total amount of PEG-lipids in the liposomes constant at 5 mole% of phospholipids (PL). Trace amounts of  $^3\text{H}$ -CHE was added to each liposome preparation and the PL concentration was calculated from the specific activity using a Beckman LS6800 Scintillation counter.

Liposomes were hydrated with 100 mM sodium acetate, 70 mM NaCl, pH 5.5 buffer. The pyridyldithio groups were reduced by the addition of dithiothreitol (DTT) to a final concentration of 20 mM for 30 min at room temperature. DTT was separated and the pH raised by passing the liposomes over a Sephadex G50 column eluted with 25 mM Hepes, 25 mM Mes, 140 mM NaCl, pH 6.7 buffer.

Thiolated liposomes (2  $\mu\text{mol}$  PL) were incubated overnight at room temperature with MPB-Ab (0.25–8 nmol) at Ab/PL molar ratios ranging from 1:250 to 1:8000, at a final PL concentration of 2–4 mM. Unbound Ab was removed by passing the liposomes over a Sepharose CL-4B column with pH 7.4 buffer (25 mM Hepes, 140 mM NaCl). The Ab to PL ratio was determined by counting for  $^{125}\text{I}$ -IgG and  $^3\text{H}$ -CHE. The amount of  $^{125}\text{I}$  in the  $^3\text{H}$  channel was subtracted from the total  $^3\text{H}$  counted and this overlap was kept below 10% of  $^3\text{H}$ .

#### 2.4. Properties of immunoliposomes

Liposomes were composed of HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE (2:1:0.08:0.02 molar ratio) or HSPC/CHOL/PDP-DOPE (2:1:0.02 molar ratio). Liposomes were hydrated with the aqueous space label  $^{125}\text{I}$ -TI [30] and prepared as above, with diameters of 98–130 nm. Free  $^{125}\text{I}$ -TI was separated from the liposomes by chromatography over a Ultragel AcA 34 column (IBF Biotechnics, France) with 25 mM Hepes, 140 mM NaCl, pH 7.4 buffer. MPB-Ab was then conjugated to PDP-containing liposomes at various ratios to give Ab surface densities of 0–140  $\mu\text{g}$  Ab/ $\mu\text{mol}$  PL.

In these experiments, the amount of Ab bound to the liposomes was determined by an adaptation of a fluo-

rescamine assay, where an increase in fluorescence is observed when fluorescamine binds to a free amino group on a protein [31,32]. Briefly, 10 mg fluorescamine was dissolved in 50 ml of dry acetonitrile. One ml samples of SIL (0.2–1 mM PL) were mixed with 1 ml of fresh fluorescamine reagent for 15 min at room temp then 1 ml of ethanol was added. The relative fluorescence was determined on a Perkin-Elmer MPF-4 spectrofluorimeter (EM 475 nm, EX 395 nm). Protein concentrations were determined from a standard curve using known concentrations of MPB-Ab (5–160  $\mu\text{g}/\text{ml}$ ).

Outbred female CD<sub>1</sub>(ICR)BR mice were purchased from Charles River Canada (St. Constant, Quebec) and maintained in standard housing. Mice (three per group) were given a single bolus i.v. injection via the tail vein of 0.2 ml of SIL (0.5  $\mu\text{mol}$  PL/mouse) containing  $(1-3) \cdot 10^5$  cpm of  $^{125}\text{I}$ -TI. At different times post-injection, animals were anaesthetized with halothane and sacrificed by cervical dislocation. Major organs (liver, spleen, lung, heart and kidney), blood (100  $\mu\text{l}$ ), thyroid and carcass (remainder of the animal) were collected and counted for  $^{125}\text{I}$  label in a Beckman 8000 gamma counter. Blood correction factors [33], were applied to all samples. The data is expressed as the percentage of counts in each organ relative to the total counts remaining in vivo at each time point [30].

The blood elimination half life of SIL was calculated using the polycapponential curve stripping and least squares parameter estimation program RSTRIP (Micromath, Salt Lake City, USA).

#### Doxorubicin loading and leakage studies

For DXR loading experiments, liposomes were hydrated in 155 mM ammonium sulfate at pH 5.5 [34]. The liposomes were then passed over a Sephadex G50 column equilibrated in 123 mM sodium citrate, pH 5.5. DXR (0.2 mg/mg PL) was then added to the liposomes and the mixture was incubated at 65°C for 1 h. DXR-containing liposomes were separated from any remaining free DXR by passage over a Sephadex G50 column and eluted with 123 mM sodium citrate pH 5.5 buffer.

For leakage experiments, DXR-loaded liposomes, composed of HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE (2:1:0.08:0.02 molar ratio), were labelled with trace amounts of  $^3\text{H}$ -CHE. Liposomes were coupled with  $^{125}\text{I}$ -Sheep IgG (SIL[sheep IgG]) to give 88  $\mu\text{g}$  Ab/ $\mu\text{mol}$  PL, then mixed with 25% human plasma in 25 mM Hepes, 140 mM NaCl, pH 7.4 at 0.6–1.2 mM PL and dialysed (Spectra/Por 2, 12000–14000  $M$ , cut-off; Spectrum, Los Angeles, Ca) against 50 volumes of 25% human plasma. At various times, samples were removed and the external plasma volume exchanged. The amount of DXR remaining in the liposomes was determined by extracting the DXR in methanol and determining the absorbance at  $A_{492}$  nm.

#### Uptake and cytotoxicity studies

Murine squamous lung carcinoma (KLN 205), human ovarian adenocarcinoma (Caov-3), and human colon

adenocarcinoma (HCT-15) cell lines were grown as monolayers in RPMI 1640 supplemented with 10% fetal bovine serum (Gibco BRL, Burlington, Ontario, Canada) at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> in air. Cells were plated in triplicate onto 6-well plates (Falcon, Becton Dickinson, Lincoln Park, NJ) at  $(0.15-1) \cdot 10^6$  cells/well on day 1. SIL were prepared by conjugating (see above), to the surface of SL (HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE, 2:1:0.08:0.02 molar ratio), mAb specific to each cell line, i.e., mAb 174H.64, B43.13 or M170 for experiments involving KLN 205, Caov-3 or HCT-15, respectively. On the fourth day (or at the point where the cells just reach confluence), SIL[174H.64], SIL[B43.13] or SIL[M170], labelled with <sup>3</sup>H-CHE (0.1–0.4 μmol/ml), in PBS were added to each well of their targeted cell lines, respectively. In some instances, binding of SIL to cells was also measured in the presence of 10% FBS. After 1 h incubation at 37°C, cells were washed three times with phosphate-buffered saline, pH 7.4, trypsinized with 0.5 ml of 0.05% trypsin, placed in ACS scintillation fluid (Amersham, Oakville, Ontario), and counted in a Beckman LS-6800 counter.

A colorimetric assay using a tetrazolium salt was used for the measurement of surviving and/or proliferating cells according to Mosmann [35]. Cells (KLN 205) were plated in 96-well plates (Corning, Corning, NY) on day 1. On the third day, cells were incubated with either free DXR, DXR entrapped in non-targeted liposomes (DXR-SL)

or DXR entrapped in SIL[174H.64] (DXR-SIL[174H.64]) and the cells were incubated for 1 h or 24 h at 37°C in a humidified 5% CO<sub>2</sub> atmosphere. At the end of the incubation, free or liposomal DXR was removed by gentle washing with phosphate-buffered saline, pH 7.4, and the cells were further incubated for 47 h or 24 h respectively, for a total of 48 h. At the end of the incubation, a solution of MTT (0.5 mg MTT/ml media) was added to each well, and the mixture was incubated at 37°C for 4 h. Acid-isopropanol (100 μl of 0.04 M HCl in isopropanol) was added to each well and mixed thoroughly until all crystals were dissolved. The plates were read immediately on a Titertek Multiskan PLUS MK II plate reader (Flow Laboratories, Mississauga, Ontario, Canada), using a test wavelength of 570 nm, and a reference wavelength of 650 nm.

### 3. Results and discussion

#### 3.1. Synthesis of PDP-PEG-DSPE

For preparation of SILs we chose the conjugation strategy shown in Fig. 1 for the following reasons. Reaction between thiol and maleimide groups is one of the most useful and efficient reactions in bioconjugate chemistry [6,36]. It takes place at close to neutral pH, at ambient temperature, within short periods of time, and often results in satisfactory yields of conjugates, even when relatively




Fig. 2. Synthetic pathways for PDP-PEG-DSPE. Both PDP-PEG-DSPE synthetic pathways started with the heterobifunctional polymer,  $\alpha$ -amino- $\omega$ -hydroxy poly(ethylene glycol) [24]. On the right,  $\alpha$ -amino- $\omega$ -hydroxy-PEG is coupled with SPDP then with DSPE. On the left,  $\alpha$ -amino- $\omega$ -hydroxy-PEG is first protected with Boc then bound to DSPE and subsequently Boc was removed and replaced with SPDP. Once incorporated into liposomes containing derivative 4, a free thiol was generated by reduction of PDP with DTT (see Materials and methods).

low concentrations of the reactants are present. Thus it seems to be particularly suitable for interlinking of two macromolecular entities.

Previous experience with maleimide-PE incorporated into liposomes showed that it interfered with the drug loading procedures [8]. Maleimide is also known to undergo gradual degradation under conditions used during liposome preparation, sizing, and drug loading steps [6,37]. On the other hand, a maleimide group can be introduced onto IgG just prior to the actual conjugation step giving it no opportunity to undergo any side reactions.

Thiol groups, while very reactive towards various electrophiles, can be preserved under non-oxidizing conditions. To absolutely assure the integrity of the thiol groups, we decided to prepare a protected form of thiol group (PDP) positioned at the terminus of PEG-DSPE. Thus, our strategy involved preparation of liposomes containing the new conjugate, PDP-PEG-DSPE, first. They were conveniently formulated and drug-loaded, and after reductive deprotection of the reactive thiol groups with DTT, conjugated with maleimide-containing IgG (see Fig. 1).

The two synthetic pathways leading to PDP-PEG-DSPE are schematically depicted in Fig. 2. The synthesis started with heterobifunctional polymer,  $\alpha$ -amino- $\omega$ -hydroxy poly(ethylene glycol), which was prepared by partial conversion of the hydroxyl end groups into primary amines [22] followed by ion-exchange purification of  $H_2N$ -PEG-OH [23]. The amino group was selectively acylated with di-*tert*-butyldicarbonate resulting in the introduction of Boc protecting group. Proton-NMR obtained in  $DMSO-d_6$  confirmed the presence of the protecting group as well as the unaltered hydroxyl. The remaining three steps of the synthesis were performed similarly to the previously published method for preparation of hydrazido-PEG-DSPE [39]. Briefly, a succinimidylcarbonate (SC) group, introduced at the hydroxy-end of the polymer, was used to form urethane attachment of the polymer to the amino group of DSPE yielding Boc-protected amino-PEG-DSPE (1) at the end of the PEG chain. The primary amine functionality was regenerated by acidolytic removal of the Boc-group forming 2. Finally, PDP-PEG-DSPE (3) was obtained by acylation of the terminal amino group with SPDP.

Alternatively  $\alpha$ -amino- $\omega$ -hydroxy-PEG could be directly reacted with SPDP substituting only the amino group. Then the remaining hydroxy end group was cleanly converted into succinimidyl carbonate and the resulting macromolecular analog of SPDP (PDP-PEG-SC) was coupled to DSPE. It appears that the second approach is preferable for a direct preparation of PDP-PEG-DSPE (3). It is two steps shorter and it resulted in higher yields of the product. The first approach is more general and allows conversion of amino-PEG-DSPE [24] into various functionalized PEG-DSPE-derivatized conjugates via use of different heterobifunctional reagents [38].

It is important to note that the utility of the new macromolecular crosslinker, PDP-PEG-SC clearly extends

Table 1  
Coupling efficiency and Ab density in liposomes containing PDP-PEG-DSPE

mol% mPEG- DSPE	mol% PDP-PEG- DSPE	Initial Ab/PL molar ratio	Ab density ( $\mu$ g Ab/ $\mu$ mol PL)	Coupling efficiency (%)
3	2	1:250	316	51
		1:500	265	85
		1:1000	136	87
4	1	1:1000	114	73
		1:2000	63	81
		1:1000	82	26
4.5	0.5	1:1000	76	48
		1:2000	66	85
		1:500	41	13
4.75	0.25	1:1000	36	23
		1:2000	35	45
5	0	1:500	11	3.4
		1:1000	10	6.1
		1:2000	7	9.5
0	1	1:1000	93	60
		1:2000	69	88

Liposomes were composed of HSPC/CHOL. 2:1 molar ratio and contained 5 mol% total PEG, consisting of a combination of mPEG-DSPE and PDP-PEG-DSPE as indicated. Liposomes averaged 100 nm in diameter. The source of Ab was sheep IgG and the Ab/PL molar ratio in the coupling mixture (2 mM PL) was varied from 1:250 to 1:2000. The coupling procedure, schematically shown in Fig. 1, is described in detail in Materials and methods. The coupling efficiency is expressed as the % of initial Ab attached to the liposomes.

beyond the current application. It is in a sense a PEG analog of SPDP and as such offers several advantages. Unlike SPDP, PDP-PEG-SC is water soluble. Since, PEG is a material of choice for rendering surfaces biocompatible, PDP-PEG-SC is perfectly suitable for linking ligands to biomaterials intended for blood plasma contact. It is ideally suited for preparation of two or more component macromolecular conjugates, e.g., protein-protein cross-linking. In this case, the PEG spacer, being very flexible and well solvated in water, would allow maximum freedom of mobility for each of the conjugated components.

### 3.2. Coupling of antibodies to liposomes containing PDP-PEG-DSPE

The PDP-PEG-DSPE could be incorporated easily into liposomes during their formation and Ab could be efficiently coupled to the surface of liposomes containing PDP-PEG-DSPE following the reduction of the PDP group with DTT. A comparison of the effect of the PDP-PEG-DSPE content in the liposomes, and the effect of Ab/PL ratio on coupling efficiency and the Ab density conjugated at the liposome surface is given in Table 1. Higher mol% of PDP-PEG-DSPE incorporated into the liposomes resulted in higher Ab densities at the liposome surface, with the highest densities being over 300  $\mu$ g Ab/ $\mu$ mol PL (Table 1) corresponding to approx. 150 Ab/100 nm diameter liposome, which is almost complete coverage of the



surface of the liposome. One can estimate that, at complete coverage, 200 Ab can be bound to a liposome 100 nm in diameter. These calculations were based on the following assumptions: the effective diameter of a IgG<sub>1</sub> molecule is 142 Å [40] (150 000 Da), the area per polar head for HSPC is 72 Å<sup>2</sup> and for CHOL is 19 Å<sup>2</sup> [41] with an combined area per phospholipid of 81.5 Å<sup>2</sup> for a HSPC/CHOL (2:1 mol/mol) liposome.

As the amount of PDP-PEG-DSPE in the liposomes was decreased, the Ab density at the liposome surface also decreased, but even at the lowest concentration of PDP-PEG-DSPE (0.25 mol%), substantial amounts of Ab still could be conjugated to the liposome surface (35–41 µg Ab/µmol PL) (Table 1). In the absence of PDP-PEG-DSPE, very low amounts of Ab were associated with the liposomes (approx. 10 µg Ab/µmol PL), possibly through passive absorption (Table 1).

When the initial Ab/PL molar ratios were kept constant (e.g., 1:1000), the coupling efficiency decreased as the concentration of PDP-PEG-DSPE in the liposomes decreased, from a high of 87% of the Ab attached to liposomes in the presence of 2 mol% PDP-PEG-DSPE to a low of 23% in the presence of 0.25 mol% PDP-PEG-DSPE (Table 1). Although Ab density decreased as the initial Ab/PL molar ratio decreased, the coupling efficiency increased as this ratio decreased. A plot of coupling efficiency versus PDP-PEG-DSPE/Ab ratio demonstrates that the % of initial Ab bound to the liposomes reaches a maximum of greater than 80% above PDP-PEG-DSPE/Ab ratios of 10:1 (Fig. 3). In other words, for maximum coupling efficiency to occur, the PDP-PEG-DSPE must be present in approximately a 10-fold excess.

In the absence of mPEG-DSPE in the liposomes, equivalent amounts of Ab became associated with the liposomes as in the presence of mPEG-DSPE, with similar coupling efficiencies (Table 1). This demonstrates that the Ab can gain easy access to its coupling site at the PEG terminus.




Fig. 3. Coupling efficiencies as a function of PDP-PEG-DSPE/Ab molar ratio. Liposomes (100 nm in diameter), composed of HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE (2:1:0.08:0.02 molar ratio), were coupled to Ab (sheep IgG) at various molar ratios of PDP-PEG-DSPE/Ab (2 mM phospholipid). The coupling efficiency is expressed as the % of initial Ab bound to the liposomes.

Table 2  
Coupling efficiency and Ab densities for liposomes containing PDP-DOPE

Initial Ab/PL molar ratio	Ab density (µg Ab/µmol PL)	Coupling efficiency (%)
1:500	28	9
1:1000	15	10
1:2000	7.4	9

Liposomes were composed of HSPC/CHOL, 2:1 molar ratio and contained 5 mol% mPEG-DSPE and 1 mol% PDP-DOPE. Liposomes averaged 100 nm in diameter. The source of Ab was sheep IgG and the Ab/PL molar ratio in the coupling mixture (2 mM PL) was varied from 1:500 to 1:2000. The coupling procedure was as outlined in Materials and methods. The coupling efficiency is expressed as the % of initial Ab attached to the liposomes.

This is in contrast to methods where Ab is coupled at the liposome surface when mPEG can sterically interfere with access of Ab to its coupling site [8]. Further data in support of this conclusion is presented in Table 2. For liposomes containing PDP-DOPE and mPEG-DSPE (i.e., the PDP group is at the liposome surface), the coupling efficiency and Ab densities are significantly lower than for liposomes containing PDP-PEG-DSPE. We suggest that this is due to steric hindrance by mPEG-DSPE to access of maleimide-Ab to the reduced PDP groups (thiol-PE) at the liposome surface.

### 3.3. Remote loading of doxorubicin and drug leakage rates

In the PDP-PEG-PE coupling method, the MPB group is attached to the Ab rather than to the liposome surface, as in coupling methods using MPB-PE [6,7]. Hence the MPB group is present in much lower concentrations, and is located much further from the immunoliposome surface after conjugation, than in the MPB-PE method. DXR could be remote loaded into SL (HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE, 2:1:0.08:0.02) prior to Ab conjugation with greater than 95% efficiency after 1 h at 65°C. The half-life for release of doxorubicin from these liposomes, following conjugation of Ab was in excess of 150 h. This is in contrast to the difficulties with the remote loading of doxorubicin into liposomes containing the MPB group at the liposome surface (MPB-PE method), where the presence of the hydrophobic MPB group at the liposome surface appears to significantly decrease the rate of loading of doxorubicin and increase the rate of drug leakage [8].

### 3.4. Pharmacokinetics of S-immunoliposomes formed by the PDP-PEG-DSPE method

Immunoliposome clearance was determined with liposomes containing the aqueous space label, <sup>125</sup>I-tyraminyl-inulin (<sup>125</sup>I-TI). Free <sup>125</sup>I-TI was removed from the body with a *t*<sub>1/2</sub> of a few minutes, while the liposome-entrapped label had a long latency time in the body with a *t*<sub>1/2</sub> of 78

h, indicating that the label had a very slow leakage rate from the liposomes in vivo. Leakage of the label was totally independent of the presence of Ab on the liposomes. The blood levels, as a function of time, for SIL containing increasing Ab densities (sheep IgG), formed by the PDP-PEG-PE method, are shown in Fig. 4A and B. Polyclonal sheep IgG was used for these experiments in order to not to deplete our limited supplies of monoclonal antibodies, however in our experience, there is no difference in the pharmacokinetics between polyclonal and monoclonal antibodies.

The addition of PDP-PEG-DSPE into S-liposomes (no Ab) did not significantly alter their circulation times ( $t_{1/2}$  of 16 h, with greater than 80% of the label remaining liposome entrapped and therefore remaining in vivo). The SIL were removed from circulation in a log-linear manner




Fig. 4. Blood clearance kinetics of S-immunoliposomes in mice. Antibody (sheep IgG) was coupled at various densities to liposomes (HSPC/CHOL/PDP-PEG-DSPE, 2:1:0.02 molar ratio  $\pm$  4 mol% mPEG-DSPE, 100 nm diameter) containing the aqueous space label  $^{125}$ I-TI. The resulting S-immunoliposomes were injected i.v., via the tail vein, into CD<sub>1</sub> (ICR) mice. Results are expressed as label remaining in blood as a percentage of the label remaining in the body at various times post injection (means  $\pm$  S.D.,  $n = 3$ ). (A) Blood clearance of S-immunoliposomes as a function of time and Ab density. Liposomes contained various Ab densities in the presence of mPEG-DSPE (●) no Ab; (▼) 20 μg Ab/μmol PL; (▲) 40 μg Ab/μmol PL; (■) 74 μg Ab/μmol PL; (●) 140 μg Ab/μmol PL. Control liposomes (◆) contained no mPEG-DSPE, and had an antibody density of 73 μg Ab/μmol PL. (B) Blood clearance of SIL at 24 h post-injection as a function of Ab density

at Ab densities of 74 μg/μmol PL and lower (Fig. 4A) and the level of SIL in blood at 24 h decreased with an increase in the Ab density (Fig. 4B). High Ab densities (140 μg/μmol PL) resulted in rapid removal of the SIL from circulation (Fig. 4A and B), but no change in the rate of label leakage from the liposomes. Ab densities in the range of approx. 20–80 μg Ab/μmol PL resulted in  $t_{1/2}$  in the circulation of from 7 to 9 h compared to 16 h in the absence of Ab (with greater than 90% of the entrapped liposome label remaining in vivo), which is likely to be sufficiently long to allow in vivo targeting. By contrast, liposomes lacking mPEG (73 μg Ab/μmol PL) were rapidly removed from circulation (Fig. 4A) even at low Ab densities, with half-lives of less than 0.5 h.

### 3.5. Binding to, and cytotoxicity to, cancer cells in culture by S-immunoliposomes

The binding by three different cancer cell lines, of SIL conjugated by the PDP-PEG-PE method to three different mAb specific for each cell line, is shown in Fig. 5. In each case the attachment of a specific mAb to SIL (SIL[174H.64], SIL[B43.13] or SIL[M170]) resulted in 2- to 3-fold increased binding of the SIL to their respective cell lines (KLN-205, Fig. 5A; Caov.3, Fig. 5B; or HCT-15, Fig. 5C). Increasing the Ab density at the liposome surface resulted in a modest increase in the amount of SIL bound to the KLN-205 cells (Fig. 5A). We have previously shown that an isotype matched non-specific Ab (B27.29, Biomira) conjugated to immunoliposomes by the PDP-PEG-PE method showed no increase in binding to KLN-205 cells compared with antibody-free liposomes [42,43]. Excess free mAb 174H.64 would compete for binding of SIL[174H.64] to KLN-205 cells, but free mAb B27.29 was not effective in displacing binding of SIL[174H.64] [42]. Incubation of HCT-15 cells in the presence of 10% FBS reduced the binding of SL (no mAb) and SIL[M170] to the cells by approx. 2-fold, but the increase in binding of SIL compared with SL was, if anything, greater in the presence of serum than in its absence (Fig. 5D versus 5C).

The ability of SIL[174H.64] to increase the cytotoxicity of entrapped DXR to KLN-205 cells was also examined (Table 3). The  $IC_{50}$  for DXR-SIL[174H.64] at 1 h incubation was lower than that for either free DXR or DXR-SL, both of which would be expected to have only low levels of non-specific association with the cells, were likely washed away before the drug could be taken up into cells in significant amounts. In addition, the very high  $IC_{50}$  for DXR-SL is likely also due to the sequestration of the DXR inside liposomes, with relatively little DXR released from the liposomes during the 1 h incubation period. As anticipated, free DXR and DXR-SL had significantly lower  $IC_{50}$  after a 24 h incubation, while the SIL[174H.64] appeared to have reached close to its maximum cytotoxicity after 1 h incubation and only experienced a slight decrease in  $IC_{50}$

Table 3  
Cytotoxicity of SIL[174H.64] against murine squamous lung carcinoma cells in culture

Sample	IC <sub>50</sub> , $\mu\text{g}$ DXR/ml of media for KLN 205 cells	
	1 h incubation	24 h incubation
Free DXR	93	15
DXR-SL	> 200	68
DXR-SIL[174H.64]	42	31

Murine squamous lung carcinoma (KLN 205) cells were plated in 96-well plates on day 1. 24 h later, free DXR, DXR-SL or DXR-SIL[174H.64] was incubated with the cells for 1 h or 24 h prior to gently washing the cells three times with phosphate-buffered saline, pH 7.4. The cells were then incubated for a further 47 or 24 h, respectively (total incubation time, 48 h). The IC<sub>50</sub> ( $\mu\text{g}$  DXR/ml) was determined from cell viability using a tetrazolium dye assay [35].

after 24 h. At 24 h, SIL[174H.64] were slightly less cytotoxic than free DXR, although more cytotoxic than DXR-SL. It would appear that the 1 h incubation period was sufficient for binding and/or internalization of the SIL[174H.64] to liposomes, as the longer incubation time did not result in very large increases in cytotoxicity for

these liposomes. The 1 h incubation would be more similar to the *in vivo* situation, where free DXR would be rapidly distributed throughout the body in a large volume of distribution [44,45], with tumor cells exposed to relatively low concentrations of the drug. The SIL, on the other hand, when bound to tumor cells *in vivo*, might be expected to deliver higher amounts of drug to the tumor in a sustained manner, either through release of locally high concentrations of drug from SIL bound at the tumor surface and uptake of DXR through the normal uptake mechanisms, or through Ab-mediated internalization of the drug-liposome package. At present we are undertaking experiments to distinguish between the relative contribution of these two mechanisms of SIL-mediated cytotoxicity, however, independent of the mechanism of cytotoxicity, we have recently demonstrated a dramatic increase in mean survival time of mice inoculated with the KLN-205 cell line and treated with DXR-SIL[174H.64] relative to DXR-SL or free DXR [46].

In conclusion, we developed a simple 3 step synthesis of new end-group functionalized PEG-lipid, PDP-PEG-DSPE, starting from  $\alpha$ -amino- $\omega$ -hydroxy-PEG. Incorpora-




Fig. 5. Binding of S-immunoliposomes by various tumor cell lines. S-immunoliposomes in PBS (HSPC/CHOL/mPEG-DSPE/PDP-PEG-DSPE, 2:1:0.08:0.02 molar ratio, 100 nm in diameter) were labelled with  $^3\text{H}$ -CHE and incubated for 1 h at 37°C with cells at a liposome concentration of 0.1–0.4  $\mu\text{mol}$  PL/ml. (A) Murine squamous lung carcinoma (KLN205) and mAb 174H.64 coupled to SIL; (B) Human ovarian adenocarcinoma (Crov-3) and mAb B43.1.3 coupled to SIL; (C) human colon adenocarcinoma (HCT-15) and mAb M170 coupled to SIL. (D) HCT-15 cells and mAb M170 coupled to SIL incubated in the presence of 10% FBS. means  $\pm$  S.D.,  $n = 3$ .

tion of this PEG-lipid conjugate into liposomes allows for convenient generation of thiol groups at the distal ends of the grafted PEG chains. Incubation of the vesicles containing thiol-PEG-DSPE (4) with maleimide-antibodies resulted in efficient conjugation even when content of the functionalized PEG-DSPE component in the liposomes was below 1 mol%. This method realizes many of the criteria which would be desirable for 'ideal' S-immunoliposomes including simplicity, high coupling efficiency, the ability to achieve a large range of Ab densities at the liposome surface, significantly increased survival times in circulation compared to classical immunoliposomes, efficient drug loading, slow drug release rates, and retention of target binding.

### Acknowledgements

This work was supported by MRC Canada (UI-12411) and Liposome Technology Inc., Menlo Park, CA. We thank Biomira Inc., Edmonton for their generous donation of monoclonal antibodies and cell lines for these experiments.

### References

- [1] Kim, S. (1994) *Drugs* 46, 618–638.
- [2] Dale, M. (1993) *Drugs Pharm. Sci.* 61, 31–63.
- [3] Gregoriadis, G. and Florence, A.T. (1993) *Drugs* 45, 15–28.
- [4] Bakkerwoordenberg, I.A.J.M., Lokerse, A.F., Tenkate, M.T., Melissen P.M.B., Vanvianen, M. and Vanetten, E.W.M. (1993) *Eur. J. Clin. Microbiol. Infect. Dis.* 12, 61–67.
- [5] Zhou, X. and Huang, L. (1992) *J. Contr. Release* 19, 269–274.
- [6] Martin, F.J. and Papahadjopoulos, D. (1981) *J. Biol. Chem.* 257, 286–288.
- [7] Weiner, A.L. (1990) in *Targeted Therapeutic Systems* (Tyle, P. and Ram, B.P., eds.), pp. 305–336, Marcel Dekker, New York.
- [8] Allen, T.M., Agrawal, A.K., Ahmad, I., Hansen, C.B. and Zalipsky, S. (1994) *J. Liposome Res.* 4, 1–25.
- [9] Torchilin, V.P. and Kilbanov, A.L. (1993) *Drug Target. Deliv.* 2, 227–238.
- [10] Aragnol, D. and Leserman, L.D. (1986) *Proc. Natl. Acad. Sci. USA* 83, 2699–2703.
- [11] Debs, R.J., Heath, T.D. and Papahadjopoulos, D. (1987) *Biochim. Biophys. Acta* 901, 183–190.
- [12] Kilbanov, A.L., Maruyama, K., Torchilin, V.P. and Huang, L. (1990) *FEBS Lett.* 268, 235–237.
- [13] Blume, G. and Cevc, G. (1990) *Biochim. Biophys. Acta* 1029, 91–97.
- [14] Allen, T.M., Hansen, C., Martin, F., Redemann, C. and Yau-Young, A. (1991) *Biochim. Biophys. Acta* 1066, 29–36.
- [15] Senior, J., Delgado, C., Fisher, D., Tilcock, C. and Gregoriadis, G. (1991) *Biochim. Biophys. Acta* 1062, 77–82.
- [16] Woodle, M.C. and Lasic, D.D. (1992) *Biochim. Biophys. Acta* 1113, 171–199.
- [17] Torchilin, V.P. and Papisov, M.I. (1994) *J. Liposome Res.* 4, 725–739.
- [18] Mori, A., Kilbanov, A.L., Torchilin, V.P. and Huang, L. (1991) *FEBS Lett.* 284, 263–266.
- [19] Kilbanov, A.L., Maruyama, K., Beckerleg, A.M., Torchilin, V.P. and Huang, L. (1991) *Biochim. Biophys. Acta* 1062, 142–148.
- [20] Blume, G., Cevc, G., Crommelin, D.J.A., Bakkerwoordenberg, I.A.J.M., Lutt, C. and Storm, G. (1993) *Biochim. Biophys. Acta* 1149, 180–184.
- [21] Maruyama, K., Takizawa, T., Yuda, T., Kennel, S.J., Huang, L. and Iwasuru, M. (1995) *Biochim. Biophys. Acta* 1234, 74–80.
- [22] Zalipsky, S., Chang, J.L., Albericio, F. and Barany, G. (1994) *Reactive Polym.* 22, 243–258.
- [23] Furukawa, S., Katayama, N., Iizuka, T., Urabe, I. and Okada, H. (1980) *FEBS Lett.* 121, 239–242.
- [24] Zalipsky, S., Brandeis, E., Newman, M. and Woodle, M.C. (1994) *FEBS Lett.* 353, 71–74.
- [25] Schimmerman, E.F., Pritchard, P.H. and Cullis, P.R. (1984) *Biochem. Biophys. Res. Commun.* 122, 319–324.
- [26] Birger, K. (1963) *Z. Anal. Chem.* 196, 251–259.
- [27] Deyl, J.M., Fang, Z.-H. and Harris, J.M. (1990) *Macromolecules* 23, 3742–3746.
- [28] Olson, F., Hunt, C.A., Szoka, F.C., Vail, W.J. and Papahadjopoulos, D. (1979) *Biochim. Biophys. Acta* 557, 9–23.
- [29] Mayer, L.D., Hope, M.J. and Cullis, P.R. (1986) *Biochim. Biophys. Acta* 858, 161–168.
- [30] Allen, T.M., Hansen, C.B. and Guo, L.L.S. (1993) *Biochim. Biophys. Acta* 1150, 9–16.
- [31] Bohlen, P., Stein, S., Dairman, W. and Udenfriend, S. (1973) *Arch. Biochem. Biophys.* 155, 213–220.
- [32] Nakai, N., Lai, C.Y. and Horrecker, B.L. (1974) *Anal. Biochem.* 58, 563–570.
- [33] Allen, T.M. (1989) in *Liposomes in the Therapy of Infectious Diseases and Cancer* (Lopez-Berestein, G. and Fidler, I., eds.), New Series, Vol. 89, pp. 405–415, Alan R. Liss, New York.
- [34] Blotkin, E.M., Cohen, R., Bar, L.K., Emanuel, N., Ninito, S., Lasic, D.D. and Barenholz, Y. (1993) *J. Liposome Res.* 4, 455–479.
- [35] Mosmann, T. (1983) *J. Immunol. Methods* 65, 55–63.
- [36] Heath, T.D. and Martin, F.J. (1986) *Chem. Phys. Lipids* 40, 347–358.
- [37] Kitagawa, T., Shimozone, T., Aikawa, T., Yoshida, T. and Nishimura, H. (1981) *Chem. Pharm. Bull.* 29, 1130–1135.
- [38] Zalipsky, S. (1995) in *Stealth Liposomes* (Lasic, D. and Martin, F., eds.), pp. 93–102, CRC Press, Boca Raton, FL.
- [39] Zalipsky, S. (1993) *Bioconjugate Chem.* 4, 296–299.
- [40] Sarma, V.R., Silverton, E.W., Davies, D.R. and Terry, W.D. (1971) *J. Biol. Chem.* 246, 3753–3759.
- [41] Lasic, D.D. (1993) *Liposomes: from physics to applications*, pp. 554–555, Elsevier, Amsterdam.
- [42] Ahmad, I. and Allen, T.M. (1992) *Cancer Res.* 52, 4817–4820.
- [43] Hansen, C.B., Kao, C.Y., Mousse, E.H., Zalipsky, S. and Allen, T.M. (1995) *Biochim. Biophys. Acta*, submitted.
- [44] Gabizon, A., Shiota, R. and Papahadjopoulos, D. (1989) *J. Natl. Cancer Inst.* 81, 1484–1488.
- [45] Gabizon, A., Catane, R., Uziel, B., Kuuffman, B., Safra, F., Cohn, R., Martin, F., Huang, A. and Barenholz, Y. (1994) *Cancer Res.* 54, 987–992.
- [46] Ahmad, I., Longenecker, M., Samuel, J. and Allen, T.M. (1993) *Cancer Res.* 53, 1484–1488.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**